Progenics Pharmaceuticals (PGNX) 10-K 13 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 07, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'PROGENICS PHARMACEUTICALS INC	'	'
Entity Central Index Key	'0000835887	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$171,517,805
Entity Common Stock, Shares Outstanding	'	69,575,404	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$65,860	$58,838
Accounts receivable, net	2,879	6,937
Other current assets	1,943	1,692
Total current assets	70,682	67,467
Auction rate securities	2,208	3,240
Fixed assets, at cost, net of accumulated depreciation and amortization	2,413	3,399
Intangible assets, net (Note 3)	31,379	0
Goodwill	7,702	0
Deferred tax assets - long term	0	2,052
Other assets	157	150
Total assets	114,541	76,308
Current liabilities:	'	'
Accounts payable and accrued expenses	6,512	5,640
Deferred tax liability - current	0	2,069
Deferred revenue - current	0	838
Other current liabilities	115	115
Total current liabilities	6,627	8,662
Contingent consideration liability	15,700	0
Deferred tax liability - long term	12,321	0
Other liabilities	914	1,078
Total liabilities	35,562	9,740
Stockholders' equity:	'	'
Preferred stock, $.001 par value; 20,000,000 shares authorized; issued and outstanding - none	0	0
Common stock, $.0013 par value; shares authorized - 160,000,000 in 2013 and 80,000,000 in 2012; issued - 61,025,404 in 2013 and 46,765,472 in 2012	79	61
Additional paid-in capital	548,510	493,613
Accumulated deficit	-466,677	-424,105
Accumulated other comprehensive loss	-192	-260
Treasury stock, at cost (200,000 shares in 2013 and 2012)	-2,741	-2,741
Total stockholders' equity	78,979	66,568
Total liabilities and stockholders' equity	$114,541	$76,308

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Stockholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, authorized (in shares)	20,000,000	20,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized (in shares)	160,000,000	80,000,000
Common stock, issued (in shares)	61,025,404	46,765,472
Treasury stock, shares (in shares)	200,000	200,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Royalty income	$5,923	$4,963	$3,046
Collaboration revenue	1,595	8,525	76,764
Research grants	275	488	4,810
Other revenues	69	72	176
Total revenues	7,862	14,048	84,796
Expenses:	'	'	'
Research and development	33,903	31,840	53,183
License fees - research and development	567	1,170	578
Royalty expense	624	499	405
General and administrative	14,809	14,706	18,248
Depreciation and amortization	939	1,324	2,066
Total expenses	50,842	49,539	74,480
Operating (loss) income	-42,980	-35,491	10,316
Other income:	'	'	'
Interest income	46	60	65
Total other income	46	60	65
Net (loss) income before provision for income taxes	-42,934	-35,431	10,381
Income tax benefit	362	0	0
Net (loss) income	($42,572)	($35,431)	$10,381
Net (loss) income per share - basic	($0.76)	($1.02)	$0.31
Weighted-average shares - basic	55,798	34,754	33,375
Net (loss) income per share - diluted	($0.76)	($1.02)	$0.31
Weighted-average shares - diluted	55,798	34,754	33,494

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME [Abstract]	'	'	'
Net (loss) income	($42,572)	($35,431)	$10,381
Other comprehensive income:	'	'	'
Net change in unrealized loss on auction rate securities	68	8	24
Total other comprehensive income	68	8	24
Comprehensive (loss) income	($42,504)	($35,423)	$10,405

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total
In Thousands
Balance, beginning at Dec. 31, 2010	$43	$453,353	($399,055)	($292)	($2,741)	$51,308
Balance, beginning (in shares) at Dec. 31, 2010	33,326	'	'	'	-200	'
Net (loss) income	0	0	10,381	0	0	10,381
Other comprehensive income	0	0	0	24	0	24
Compensation expenses for share-based payment arrangements	0	6,362	0	0	0	6,362
Forfeitures of restricted stock	0	0	0	0	0	0
Forfeitures of restricted stock (in shares)	-38	'	'	'	0	'
Sale of common stock under employee stock purchase plans and exercise of stock options	1	3,725	0	0	0	3,726
Sale of common stock under employee stock purchase plans and exercise of stock options (in shares)	758	'	'	'	0	'
Balance, ending at Dec. 31, 2011	44	463,440	-388,674	-268	-2,741	71,801
Balance, ending (in shares) at Dec. 31, 2011	34,046	'	'	'	-200	'
Net (loss) income	0	0	-35,431	0	0	-35,431
Other comprehensive income	0	0	0	8	0	8
Compensation expenses for share-based payment arrangements	0	6,536	0	0	0	6,536
Forfeitures of restricted stock	0	0	0	0	0	0
Forfeitures of restricted stock (in shares)	-6	'	'	'	0	'
Sale of common stock in public offering, net of underwriting discounts and commissions and offering expenses	17	23,331	0	0	0	23,348
Sale of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares)	12,650	'	'	'	0	'
Sale of common stock under employee stock purchase plans and exercise of stock options	0	306	0	0	0	306
Sale of common stock under employee stock purchase plans and exercise of stock options (in shares)	75	'	'	'	0	'
Balance, ending at Dec. 31, 2012	61	493,613	-424,105	-260	-2,741	66,568
Balance, ending (in shares) at Dec. 31, 2012	46,765	'	'	'	-200	'
Net (loss) income	0	0	-42,572	0	0	-42,572
Other comprehensive income	0	0	0	68	0	68
Compensation expenses for share-based payment arrangements	0	3,546	0	0	0	3,546
Forfeitures of restricted stock	0	0	0	0	0	0
Forfeitures of restricted stock (in shares)	-1	'	'	'	0	'
Acquisition of subsidiary, net of issuance costs	6	11,214	0	0	0	11,220
Stock Issued During Period, Shares, Acquisitions	4,472	'	'	'	0	'
Sale of common stock in public offering, net of underwriting discounts and commissions and offering expenses	12	40,066	0	0	0	40,078
Sale of common stock in public offering, net of underwriting discounts and commissions and offering expenses (in shares)	9,775	'	'	'	0	'
Sale of common stock under stock incentive plan and exercise of stock options	0	71	0	0	0	71
Sale of common stock under stock incentive plan and exercise of stock options (in shares)	14	'	'	'	0	'
Balance, ending at Dec. 31, 2013	$79	$548,510	($466,677)	($192)	($2,741)	$78,979
Balance, ending (in shares) at Dec. 31, 2013	61,025	'	'	'	-200	'

CONSOLIDATED_STATEMENTS_OF_STO1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Underwriting discounts and commissions	$2,581	$1,518
Offering expenses	$351	$434

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net (loss) income	($42,572)	($35,431)	$10,381
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:	'	'	'
Depreciation and amortization	939	1,324	2,066
Gains on sales of fixed assets	204	-327	0
Intangible impairment charge	919	0	0
Deferred income tax	-362	0	0
Change in contingent consideration liability	-200	0	0
Expenses for share-based compensation awards	3,546	6,536	6,362
Changes in assets and liabilities:	'	'	'
(Increase) decrease in accounts receivable	4,114	-5,421	767
(Increase) decrease in other current assets	336	-754	882
(Increase) decrease in deferred tax and other assets	2,044	-2,002	1,050
(Decrease) increase in accounts payable and accrued expenses	-1,956	-691	-3,352
(Decrease) increase in deferred revenue - current	-886	634	204
Increase (decrease) in deferred tax and other current liabilities	-2,069	2,069	3
(Decrease) increase in deferred revenue - long term	0	-162	162
(Decrease) increase in other liabilities	-164	-419	-138
Net cash (used in) provided by operating activities	-36,107	-34,644	18,387
Cash flows from investing activities:	'	'	'
Cash acquired in acquisition of subsidiary	1,888	0	0
Capital expenditures	-137	-767	-226
Proceeds from sales of fixed assets	174	390	0
Proceeds from redemption of auction rate securities	1,100	100	300
Net cash (used in) provided by investing activities	3,025	-277	74
Cash flows from financing activities:	'	'	'
Equity issuance costs in connection with acquisition of subsidiary	-45	0	0
Proceeds from public offering of common stock, net of underwriting discounts and commissions and offering expenses	40,078	23,348	0
Proceeds from the exercise of stock options and sale of common stock under the employee stock purchase plans	71	306	3,726
Net cash provided by financing activities	40,104	23,654	3,726
Net (decrease) increase in cash and cash equivalents	7,022	-11,267	22,187
Cash and cash equivalents at beginning of period	58,838	70,105	47,918
Cash and cash equivalents at end of period	65,860	58,838	70,105
Supplemental Cash Flow Elements [Abstract]	'	'	'
Contingent consideration liability	15,700	0	0
Stock acquisition consideration	$11,265	$0	$0

Organization_and_Business

Organization and Business	12 Months Ended
	Dec. 31, 2013
Organization and Business [Abstract]	'
Organization and Business	'
	1. Organization and Business
	Progenics Pharmaceuticals, Inc. ("Progenics," "we" or "us") develops innovative medicines for oncology. Our clinical development efforts center on late-stage oncology assets. We are conducting phase 2 clinical trials of two product candidates for prostate cancer: our therapeutic candidate, PSMA ADC, a fully human monoclonal antibody-drug conjugate (ADC), and 1404 (trofolastat), an imaging agent candidate, and resuming a pivotal phase 2 clinical trial of Azedra™, our ultra-orphan radiotherapy candidate for pheochromocytoma. We have also decided to move forward MIP-1095, a compound originally developed by Molecular Insight, into clinical development, and expect to file an IND application in the U.S. later this year.
	We have licensed our first commercial drug, Relistor® (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid induced constipation (OIC), to Salix Pharmaceuticals, Inc., and have partnered other internally-developed or acquired compounds and technologies with third parties. We continue to consider opportunities for strategic collaborations, out-licenses and other arrangements with biopharmaceutical companies involving proprietary research, development and clinical programs, and may in the future also in-license or acquire additional oncology compounds and/or programs.
	Our current principal sources of revenue from operations are royalty, commercialization milestone and revenue-sharing payments from Salix's Relistor operations. Royalty and milestone payments from Relistor depend on success in development and commercialization, which is dependent on many factors, such as Salix's efforts, decisions by the FDA and other regulatory bodies such as the July 2012 Complete Response Letter in respect of the Relistor chronic pain sNDA, competition from drugs for the same or similar indications, and the outcome of clinical and other testing of Relistor.
	We fund our operations to a significant extent from capital-raising.  During 2013, we completed an underwritten public offering of 9.8 million shares of common stock at a public offering price of $4.40 per share, resulting in net proceeds of approximately $40.1 million, and in early 2014 sold an additional 8.75 million shares at $4.60 per share for net proceeds of approximately $37.5 million.
	Progenics commenced principal operations in 1988, became publicly traded in 1997 and throughout has been engaged primarily in research and development efforts, establishing corporate collaborations and related activities. Certain of our intellectual property rights are held by wholly owned subsidiaries. All of our operations are conducted at our facilities in Tarrytown, New York. We operate under a single research and development segment.
	Funding and Financial Matters. At December 31, 2013, we held $65.9 million in cash and cash equivalents, an increase of $7.1 million from $58.8 million at December 31, 2012. We expect that this amount, together with the additional 2014 public offering proceeds, will be sufficient to fund operations as currently anticipated beyond one year. We may require additional funding in the future, and if we are unable to conclude favorable collaboration, license, asset sale, capital raising or other financing transactions, we will have to reduce, delay or eliminate spending on some current operations, and/or reduce salary and other overhead expenses, to extend our remaining operations. We expect to incur operating losses during the near term. At December 31, 2013, cash, cash equivalents and auction rate securities increased $6.0 million to $68.1 million from $62.1 million at December 31, 2012.

Acquisition_of_Molecular_Insig

Acquisition of Molecular Insight Pharmaceuticals, Inc	12 Months Ended
	Dec. 31, 2013
Acquisition of Molecular Insight Pharmaceuticals, Inc [Abstract]	'
Acquisition of Molecular Insight Pharmaceuticals, Inc	'
	2.  Acquisition of Molecular Insight Pharmaceuticals, Inc.
	Molecular Insight's operations from January 18, 2013, the date we acquired this subsidiary which significantly expanded the Company's focus on PSMA as an oncology target while broadening the oncology pipeline, are included in the Consolidated Financial Statements. The acquisition consideration included 4,566,210 shares (500,000 of which were placed in an escrow expiring in April 2014) of Progenics common stock in a private transaction not taxable to Progenics. (The closing NASDAQ market price of Progenics' freely transferable common shares on January 18, 2013 was $2.83 per share.) Under the acquisition agreement, Progenics also agreed to pay to the stockholders potential milestones, in cash or Progenics stock at Progenics' option, of up to $23 million contingent upon achieving specified commercialization events and up to $70 million contingent upon achieving specified sales targets relating to all MIP products. Of the 500,000 placed in escrow,  shares have been returned to Progenics to date pursuant to financial adjustment provisions of the agreement.
	The acquisition was accounted for using the acquisition method of accounting, under which assets and liabilities of the acquired entity are recorded at their respective fair values as of the acquisition date (estimated as described below) and added to those of the acquiring entity. The difference between the estimated fair value of the acquisition consideration paid and fair value of the identifiable net assets represents potential future economic benefits arising from combining Progenics and MIP, taking into account a deferred tax liability related to in process research and development (IPR&D) intangible assets, and has been recorded as goodwill. The results of operations of MIP's business, the estimated fair market values of the assets acquired and liabilities assumed, and goodwill are included in our consolidated financial statements since the date of the acquisition.
	During the year ended December 31, 2013, the Company incurred $790 in transaction costs related to the acquisition, which primarily consisted of legal, accounting and valuation-related expenses and reduced additional paid-in capital in the first quarter of 2013 by $45 for acquisition-related equity issuance costs. The transaction costs were recorded in general and administrative expenses in the accompanying consolidated statements of operations. During the year ended December 31, 2013, MIP's business contributed $884 of revenues and $11,379 of net loss.
	Purchase Price Allocation: We have accounted for the Molecular Insight acquisition by allocating our estimate of the fair market value of the consideration we paid to the fair values of the assets acquired and liabilities assumed at the effective date of the acquisition, estimated using the valuation models summarized below. Given the uniqueness of and uncertainties attendant to the assets and liabilities, the derived values do not reflect actual transactions or quoted prices. Acquired intangible assets, including goodwill, are not deductible for tax purposes.
		Amount
	Consideration:
	Progenics common stock consideration paid	$	11,265
	Contingent consideration (pursuant to future milestone obligations)		15,900
	Total consideration		27,165
	Tangible assets acquired and liabilities assumed:
	Cash and cash equivalents		1,888
	Accounts receivable		56
	Other current assets		529
	Fixed assets		249
	Accounts payable, accrued expenses and deferred revenue - current		(2,876	)
	Deferred tax liability – long term		(12,683	)
	Total tangible assets acquired and liabilities assumed		(12,837	)
	Intangible assets – in process research and development		32,300
	Total tangible and intangible assets acquired and liabilities assumed		19,463
	Goodwill	$	7,702
	Intangible assets and goodwill: In connection with the acquisition of Molecular Insight, in process research and development and goodwill are initially measured at estimated fair value and capitalized as an intangible asset. We perform an impairment test for these intangibles annually in the fourth quarter, unless impairment indicators require an earlier evaluation. Upon and subject to commercialization of the Company's product candidates, the IPR&D will be amortized over its estimated useful life.
	We valued as intangible assets the in process research and development projects acquired as follows:
	(i) 1404, an imaging agent in phase 2 development, at an estimated fair value of $23.2 million resulting from a probability adjusted discounted cash flow model which includes estimates of significant cash inflows beginning in 2017 and a 18% discount rate;
	(ii) Azedra, a small molecule candidate for the treatment of pheochromocytoma and paraganglioma in phase 2b development, and for neuroblastoma in phase 2a development, at an estimated fair value of $4.9 million resulting from a probability adjusted discounted cash flow model which includes estimates of significant cash inflows beginning in 2017 and a 15% discount rate;
	(iii) small molecule candidate MIP-1095, in preclinical development for the treatment of prostate cancer, at an estimated fair value of $2.7 million resulting from a probability adjusted discounted cash flow model which includes estimates of significant cash inflows beginning in 2021 and a 20% discount rate; and
	(iv) Onalta, a drug candidate in phase 2 development for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors, at an estimated fair value of $1.5 million resulting from a probability adjusted discounted cash flow model which includes estimates of significant cash inflows beginning in 2014 and a 15% discount rate.
	On the acquisition date, we recorded a contingent consideration liability at an estimated fair value of $15.9 million resulting from probability adjusted discounted cash flow and Monte Carlo simulation models which include estimates of significant milestone payments to former MIP stockholders under the acquisition agreement ranging from 2016 to 2022 and risk adjusted discount rates ranging from 10% to 12.5%.
	Pro forma financial information (unaudited): The following unaudited pro forma information presents the results of operations of the combined companies for the periods indicated as if the acquisition had been consummated on January 1, 2012, combining the respective historical results of Progenics and MIP for each period. Non-recurring transaction expenses of $790, incurred in the year ended December 31, 2013, are reflected in the pro forma information as if these were incurred in the corresponding 2012 period, due to the pro forma assumption of January 1, 2012 as the date of the acquisition consummation.
		Three Months Ended						Year Ended
		December 31,						December 31,
		2013			2012			2013			2012
	Revenues	$	2,968		$	12,801		$	7,867		$	18,235
	Net loss		(8,551	)		(3,458	)		(43,736	)		(57,877	)
	Basic and diluted loss per share		(0.14	)		(0.08	)		(0.78	)		(1.48	)

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	3. Summary of Significant Accounting Policies
	Basis of Presentation
	The consolidated financial statements have been prepared on the basis of accounting principles generally accepted in the U.S. (GAAP). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, the Company evaluates its estimates, including but not limited to those related to collectability of receivables, intangible assets and contingencies. As additional information becomes available or actual amounts become determinable, the recorded estimates are revised and reflected in the operating results. Actual results could differ from those estimates.
	Consolidation
	The consolidated financial statements include the accounts of Progenics and PSMA LLC, as of and for the years ended December 31, 2013, 2012 and 2011 and Molecular from January 18, 2013, the date we acquired this subsidiary. Inter-company transactions have been eliminated in consolidation.
	Revenue Recognition
	We recognize revenue from all sources based on the provisions of the SEC's Staff Accounting Bulletin (SAB) No. 104 (SAB 104) and ASC 605 Revenue Recognition. Under ASC 605, delivered items are separate units of accounting, provided (i) the delivered items have value to a collaborator on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered items is considered probable and substantially in our control. A separate update to ASC 605 provides guidance on the criteria that should be met when determining whether the milestone method of revenue recognition is appropriate.
	If we are involved in a steering or other committee as part of a multiple-deliverable arrangement, we assess whether our involvement constitutes a performance obligation or a right to participate. For those committees that are deemed obligations, we will evaluate our participation along with other obligations in the arrangement and will attribute revenue to our participation through the period of our committee responsibilities. We recognize revenue for payments that are contingent upon performance solely by our collaborator immediately upon the achievement of the defined event if we have no related performance obligations. Reimbursement of costs is recognized as revenue provided the provisions of ASC 605 are met, the amounts are determinable and collection of the related receivable is reasonably assured.
	Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Amounts not expected to be recognized within one year of the balance sheet date are classified as long-term. The estimate of the classification of deferred revenue as short- or long-term is based upon the period in which we expect to perform joint committee services.
	Royalty revenue is recognized in the period the sales occur, provided the royalty amounts are fixed or determinable, collection of the related receivable is reasonably assured and we have no remaining performance obligations under the arrangement providing for the royalty.
	During the past three years, we also recognized revenue from sales of research reagents and from government research grants, awarded to us by the National Institutes of Health (NIH), which we used in proprietary research programs. NIH grant revenue is recognized as efforts are expended and as related program costs are incurred. We performed work under the NIH grants on a best-effort basis.
	Under Molecular's 2013 license of certain research, development and commercialization rights to Onalta™, we received a $0.2 million in upfront payment and are eligible for future milestone and royalty payments. In consideration for the upfront payment, we have delivered relevant know-how (including patent rights), inventory and non-reimbursable services.
	In the fourth quarter of 2012, we out-licensed our C. difficile program to MedImmune, LLC for a $5.0 million upfront payment, and the right to receive potential future milestone and royalty payments. In consideration for the upfront payment, we have delivered relevant know-how (including patent rights) and non-reimbursable services.
	Under our 2012 agreement with CytoDyn Inc. for our PRO 140 program, we received $3.5 million payment and are eligible for future milestone and royalty payments. In consideration for the upfront payment, we have delivered relevant know-how (including patent rights), inventory and non-reimbursable services.
	Under our license agreement, Salix is responsible for further developing and commercializing Relistor worldwide other than Japan. In consideration of the $60.0 million upfront payment from Salix, we have granted Salix an exclusive license of relevant know-how, patent rights and technology, assigned relevant third-party contracts, and served on joint committees provided for in the License Agreement through end of 2013.
	These deliverables, which have stand-alone value and represent separate units of accounting, include (i) the exclusive license which was delivered for revenue recognition purposes during the 2011 second quarter, (ii) performing reimbursable development services at Salix's direction during the 2011 second quarter, the period in which we and Salix finalized the development plan, and (iii) joint committee services, which have been performed through 2013. We determined that the license has stand-alone value as the license was delivered to Salix for revenue recognition purposes in the second quarter of 2011 and Salix is responsible for continuing research and development.
	We developed a best estimate of selling price for each deliverable as vendor-specific objective evidence and third-party evidence was not available. We allocated the best estimate of selling price, on a relative basis, to each of the three units of accounting as the $60.0 million upfront payment was the only payment from Salix which was fixed and determinable at the inception of the arrangement. As a result, $58.4 million, $1.1 million and $0.5 million was allocated to the license, reimbursable development services and our participation in the joint committees as provided in the License Agreement, respectively. We recognized $58.4 million for the license and relevant know-how, patent rights and technology and $1.1 million for the reimbursable development services, respectively, during the second quarter of 2011, the period in which we delivered these items and performed the development services. We recognized $0.2 million, $0.2 million and $59.6 million during 2013, 2012 and 2011, respectively. At December 31, 2012, the remaining deferred revenue of $0.2 million, pertaining to joint committee services, was recognized as collaboration revenue in 2013, as such activities were performed.
	Ono is responsible for developing and commercializing subcutaneous Relistor in Japan, including conducting the clinical development necessary to support regulatory marketing approval. Ono will own the filings and approvals related to subcutaneous Relistor in Japan. In addition to the $15.0 million upfront payment from Ono, we are entitled to receive up to an additional $20.0 million, payable upon achievement by Ono of its development milestones. Ono is also obligated to pay to us royalties and commercialization milestones on sales by Ono of subcutaneous Relistor in Japan. Ono has the option to acquire from us the rights to develop and commercialize in Japan other formulations of Relistor, including intravenous and oral forms, on terms to be negotiated separately. Ono may request us to perform activities related to its development and commercialization responsibilities, beyond our participation in joint committees and specified technology transfer-related tasks, at its expense payable at the time we perform such services. Revenue earned from activities we perform for Ono is recorded in collaboration revenue.  See Note 10.
	Research and Development Expenses
	Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, maintenance of research equipment, costs related to research collaboration and licensing agreements, the purchase of in-process research and development, the cost of services provided by outside contractors, including services related to our clinical trials, the full cost of manufacturing drug for use in research, pre-clinical development and clinical trials. All costs associated with research and development are expensed as incurred.
	At each period end, we evaluate the accrued expense balance related to these activities based upon information received from the suppliers and estimated progress towards completion of the research or development objectives to ensure that the balance is reasonably stated. Such estimates are subject to change as additional information becomes available.
	Use of Estimates
	Significant estimates include useful lives of fixed assets, the periods over which certain revenues and expenses will be recognized, including collaboration revenue recognized from non-refundable up-front licensing payments and expense recognition of certain clinical trial costs which are included in research and development expenses, the amount of non-cash compensation costs related to share-based payments to employees and non-employees and the periods over which those costs are expensed, the likelihood of realization of deferred tax assets and the assumptions used in the valuations of in-process research and development and contingent consideration liability.
	Patents
	As a result of research and development efforts conducted by us, we have applied, or are applying, for a number of patents to protect proprietary inventions. All costs associated with patents are expensed as incurred.
	Net (Loss) Income Per Share
	We prepare earnings per share (EPS) data in accordance with ASC 260 Earnings Per Share. Basic net (loss) income per share amounts have been computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period. For 2013 and 2012, we reported net losses and, therefore, potential common shares, amounts of unrecognized compensation expense and windfall tax benefits have been excluded from diluted net loss per share since they would be anti-dilutive. For 2011, we reported net income, and the computation of diluted earnings per share is based upon the weighted-average number of our common shares and dilutive effect, determined using the treasury stock method, of potential common shares outstanding including amounts of unrecognized compensation expense. As of December 31, 2012 and 2011, 28 and 98, respectively, shares of unvested restricted stock outstanding have non-forfeitable rights to dividends; all such shares were vested at the end of December 31, 2013. The allocation of 2013 and 2012 net losses and the 2011 net income to these participating securities pursuant to the two-class method is not material to both basic and diluted earnings per share.
	Concentrations of Credit Risk
	Financial instruments which potentially subject Progenics to concentrations of risk consist principally of cash, cash equivalents, auction rate securities and receivables. We invest our excess cash in money market funds. We have established guidelines that relate to credit quality, diversification and maturity and that limit exposure to any one issue of securities. We hold no collateral for these financial instruments.
	Cash and Cash Equivalents
	We consider all highly liquid investments which have maturities of three months or less, when acquired, to be cash equivalents. The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value. Cash and cash equivalents subject us to concentrations of credit risk. At December 31, 2013 and 2012, we have invested approximately $60,364 and $56,224, respectively, in cash equivalents in the form of money market funds with one major investment company and held approximately $4,898 and $2,614, respectively, in a single commercial bank.
	Accounts Receivable
	We estimate the level of accounts receivable which ultimately will be uncollectable based on a review of specific receivable balances, industry experience and the current economic environment. We reserve for affected accounts receivable an allowance for doubtful accounts, which at December 31, 2013 was $7.
	Auction Rate Securities
	In accordance with ASC 320 Investments – Debt and Equity Securities, investments are classified as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in comprehensive (loss) income. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income or expense. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. In computing realized gains and losses, we compute the cost of its investments on a specific identification basis. Such cost includes the direct costs to acquire the securities, adjusted for the amortization of any discount or premium. The fair value of auction rate securities has been estimated based on a three-level hierarchy for fair value measurements. Interest and dividends on securities classified as available-for-sale are included in interest income (see Note 4).
	At December 31, 2013 and 2012, our investment in auction rate securities (recorded as long-term assets in the Consolidated Balance Sheets) amounted to $2,208 and $3,240, respectively. Valuation of securities is subject to uncertainties that are difficult to predict, such as changes to credit ratings of the securities and/or the underlying assets supporting them, default rates applicable to the underlying assets, underlying collateral value, discount rates, counterparty risk, ongoing strength and quality of market credit and liquidity and general economic and market conditions. The valuation of the auction rate securities we hold is based on an internal analysis of timing of expected future successful auctions, collateralization of underlying assets of the security and credit quality of the security. We re-evaluated the valuation of these securities as of December 31, 2013 and the temporary impairment amount decreased $68 from $260 at December 31, 2012 to $192. All income generated from these investments was recorded as interest income (see Note 4).
	In-Process Research and Development and Goodwill
	The fair values of in-process research and development (IPR&D) acquired in business combinations are capitalized. The Company utilizes the "income method," which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each project independently. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. IPR&D intangible assets which are determined to have a decline in their fair value are adjusted downward and an expense is recognized as part of the general and administrative expenses in the Consolidated Statements of Operations. These are tested at least annually or when a triggering event occurs that could indicate a potential impairment.
	Goodwill represents excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized, but is subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment. The Company determines whether goodwill may be impaired by comparing the fair value of the reporting unit, calculated as the product of shares outstanding and the share price as of the end of a period, to its carrying value. No goodwill impairment has been recognized as of December 31, 2013. The Company has determined that it has only one reporting unit, which includes the acquired Molecular Insight.
	The following table reflects the components of the finite lived intangible assets as of December 31, 2013:
			Gross		Accumulated			Net Carrying
			Amount		Amortization			Value
	Finite lived intangible assets		$	21	$	2		$	19
	Total		$	21	$	2		$	19
	The weighted-average remaining life of the finite lived intangible assets is five years at December 31, 2013.
	Amortization expense is calculated on a straight-line basis over the estimated useful life of the asset. Amortization expense for the period from January 18, 2013 to December 31, 2013 was $2. Estimated amortization expense related to intangible assets existing as of December 31, 2013 is approximately $4 annually for each of the succeeding five years.
	The following table summarizes the activity related to the Company's goodwill and indefinite lived IPR&D:
			Goodwill		IPR&D
	Balance at January 1, 2013		$	-	$	-
	Increase related to MIP acquisition			7,702		32,300
	Reclassification to finite lived IPR&D			-		(21	)
	Impairment			-		(919	)
	Balance at December 31, 2013		$	7,702	$	31,360
	Fair Value Measurements
	In accordance with ASC 820 Fair Value Measurements and Disclosures, we use a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). We assign hierarchy levels to assets constituting our available-for-sale portfolio and to our contingent consideration liability arising from the MIP acquisition based on our assessment of the transparency and reliability of the inputs used in the valuation. ASC 820 defines the three hierarchy levels as:
	·	Level 1 - Valuations based on unadjusted quoted market prices in active markets for identical securities.
	·	Level 2 - Valuations based on observable inputs other than Level 1 prices, such as quoted prices for similar assets at the measurement date, quoted prices in markets that are not active or other inputs that are observable, either directly or indirectly.
	·	Level 3 - Valuations based on unobservable inputs that are significant to the overall fair value measurement, which as noted above involve management judgment.
	Recurring Fair Value Measurements
	We believe the carrying amounts of the Company's cash equivalents, accounts receivable, other current assets, other assets (restricted cash providing collateral for a letter of credit securing lease obligations) and accounts payable and accrued expenses approximated their fair values as of December 31, 2013 and 2012, due to their short-term nature; we consider them Level 1 instruments.
	The fair value of the contingent consideration liability, consisting of future potential milestone payments related to the MIP acquisition was $15.7 million as of December 31, 2013 and $15.9 million as January 18, 2013, the acquisition date (see Note 2). The fair value of the contingent consideration liability is categorized as a Level 3 instrument, as displayed in Note 4. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the Consolidated Statements of Operations. As of December 31, 2013, we reassessed the fair value of the contingent consideration and recorded a $0.2 million decrease, due to an increase in the discount period, and a corresponding credit in the general and administrative expenses in the fourth quarter of 2013. The December 31, 2013 contingent consideration of $15.7 million results from probability adjusted discounted cash flow and Monte Carlo simulation models which include estimates of significant milestone payments to former MIP stockholders under the acquisition agreement ranging from 2017 to 2022 and risk adjusted discount rates ranging from 10% to 12.5%.
	Nonrecurring Fair Value Measurements
	The Company's non-financial assets, such as intangible assets and property and equipment, are measured and recorded at fair value on the acquisition date, and if indicators of impairment exist, we assess recoverability by measuring the amount of any impairment by comparing the carrying value of the asset to its then-current estimated fair value (for intangible assets) or to market prices for similar assets (for property and equipment). If the carrying value is not recoverable we record an impairment charge as a general and administrative expense in the Consolidated Statements of Operations. The company reassessed the value of the indefinite lived intangible assets and recorded a non-cash charge to earnings of $919 in the fourth quarter of 2013. This impairment was the result of change in the Level 3 assumptions: (i) the timing of the estimated beginning of cash inflows from 2014 to 2018 and (ii) an increase in discount rate from 15% to 18% for the Onalta intangible asset. In connection with the second quarter amendment of the Company's Tarrytown lease, we recognized impairment losses of $347 on leasehold improvements and machinery and equipment removed from service which are included in Research and development expenses in our accompanying Consolidated Statements of Operations for the year ended December 31, 2013. As a result of closing our biologics pilot facilities in 2011, an impairment loss of $22 was included in Research and development expenses in our accompanying Consolidated Statement of Operations during 2011. No impairments occurred for the year ended December 31, 2012.
Other current assets are comprised of prepaid expenses, interest, deferred tax asset and other receivables of $1,943 and $1,692 at December 31, 2013 and 2012, respectively, which are expected to be settled within one year. Restricted cash of $157 and $150 at December 31, 2013 and 2012, respectively, consists of collateral for a letter of credit securing lease obligations. We believe the carrying value of these assets approximates fair value.
Fixed Assets
Leasehold improvements, furniture and fixtures, and equipment are stated at cost. Furniture, fixtures and equipment are depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized on a straight-line basis over the life of the lease or of the improvement, whichever is shorter. Costs of construction of long-lived assets are capitalized but are not depreciated until the assets are placed in service.
Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred. The cost and accumulated depreciation of assets retired or sold are removed from the respective accounts and any gain or loss is recognized in operations. The estimated useful lives of fixed assets are as follows:
Computer equipment	3 years
Machinery and equipment	5-7 years
Furniture and fixtures	5 years
Leasehold improvements	Earlier of life of improvement or lease
Deferred Lease Liability and Incentive
Our lease agreements include fixed escalations of minimum annual lease payments and we recognize rental expense on a straight-line basis over the lease terms and record the difference between rent expense and current rental payments as deferred rent. Deferred lease incentive includes a construction allowance from our landlord which is amortized as a reduction to rental expense on a straight-line basis over the lease term. As of December 31, 2013 and 2012, the Consolidated Balance Sheets include the following:
		2013		2012
Other current liabilities:
Deferred lease incentive		$	115	$	115
Total other current liabilities		$	115	$	115
Other liabilities:
Deferred lease liability		$	224	$	273
Deferred lease incentive			690		805
Total other liabilities		$	914	$	1,078
Income Taxes
We account for income taxes in accordance with the provisions of ASC 740 Income Taxes, which requires that we recognize deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. A valuation allowance is established for deferred tax assets for which realization is uncertain.
In accordance with ASC 718 Compensation – Stock Compensation and ASC 505 Equity, we have made a policy decision related to intra-period tax allocation, to account for utilization of windfall tax benefits based on provisions in the tax law that identify the sequence in which amounts of tax benefits are used for tax purposes (i.e., tax law ordering).
Uncertain tax positions are accounted for in accordance with ASC 740 Income Taxes, which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that we have taken or expect to take on a tax return. ASC 740 applies to income taxes and is not intended to be applied by analogy to other taxes, such as sales taxes, value-add taxes, or property taxes. We review our nexus in various tax jurisdictions and our tax positions related to all open tax years for events that could change the status of our ASC 740 liability, if any, or require an additional liability to be recorded. Such events may be the resolution of issues raised by a taxing authority, expiration of the statute of limitations for a prior open tax year or new transactions for which a tax position may be deemed to be uncertain. Those positions, for which management's assessment is that there is more than a 50 percent probability of sustaining the position upon challenge by a taxing authority based upon its technical merits, are subjected to the measurement criteria of ASC 740. We record the largest amount of tax benefit that is greater than 50 percent likely of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. Any ASC 740 liabilities for which we expect to make cash payments within the next twelve months are classified as "short term." In the event that we conclude that we are subject to interest and/or penalties arising from uncertain tax positions, we will record interest and penalties as a component of income taxes (see Note 13).
Risks and Uncertainties
We have to date relied principally on external funding, collaborations with Salix, Fuji and others, out-licensing and asset sale arrangements, royalty and product revenue to finance our operations. There can be no assurance that our research and development will be successfully completed, that any products developed will obtain necessary marketing approval by regulatory authorities or that any approved products will be commercially viable. In addition, we operate in an environment of rapid change in technology, and we are dependent upon satisfactory relationships with our partners and the continued services of our current employees, consultants and subcontractors. We are also dependent upon Salix, Fuji and Ono fulfilling their manufacturing obligations, either on their own or through third-party suppliers. For 2013, 2012 and 2011, the primary sources of our revenues were Salix, Ono, Fuji, asset out-licensing and disposition, and research grant revenues from the NIH. There can be no assurance that revenues from asset out-licensing and disposition, Salix, Ono and Fuji or from research awards will continue. Substantially all of our accounts receivable at December 31, 2013 and 2012 were from the above-named sources.
Comprehensive (Loss) Income
Comprehensive (loss) income represents the change in net assets of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive (loss) income includes net (loss) income adjusted for the change in net unrealized gain or loss on auction rate securities. The disclosures required by ASC 220 Comprehensive Income for 2013, 2012 and 2011 have been included in the Consolidated Statements of Comprehensive (Loss) Income. There was no income tax expense/benefit allocated to any component of Other Comprehensive (Loss) Income (see Note 13).
Impact of Recently Adopted Accounting Standards
In February 2013, the FASB issued ASU No. 2013-02, which requires presentation of amounts reclassified out of accumulated other comprehensive income by component. The ASU is effective for reporting periods beginning after December 15, 2012. We adopted this new standard on January 1, 2013 and it had no material impact on our consolidated financial statements.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	4. Fair Value Measurements
	We record auction rate securities at fair value in the accompanying Consolidated Balance Sheets in accordance with ASC 320 Investments – Debt and Equity Securities. The change in the fair value of these securities is recorded as a component of other comprehensive (loss) income. We also record the contingent consideration liability resulting from the MIP acquisition at fair value in accordance with ASC 820-10-50.
	The following tables present our money market funds, included in cash and cash equivalents, and auction rate securities assets and contingent consideration liability measured at fair value on a recurring basis as of the dates indicated, classified by valuation hierarchy:
						Fair Value Measurements at December 31, 2013
		Balance at				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs		Significant Unobservable Inputs
		31-Dec-13				(Level 1)				(Level 2)		(Level 3)
	Assets:
	Money market funds	$	60,364			$	60,364			$	-	$	-
	Auction rate securities		2,208				-				-		2,208
	Total Assets	$	62,572			$	60,364			$	-	$	2,208
	Liability:
	Contingent consideration	$	15,700			$	-			$	-	$	15,700
	Total Liability	$	15,700			$	-			$	-	$	15,700
						Fair Value Measurements at December 31, 2012
		Balance at				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs		Significant Unobservable Inputs
		31-Dec-12				(Level 1)				(Level 2)		(Level 3)
	Money market funds	$	56,224			$	56,224			$	-	$	-
	Auction rate securities		3,240				-				-		3,240
	Total	$	59,464			$	56,224			$	-	$	3,240
	At December 31, 2013, we hold $2,208 in auction rate securities which are classified as Level 3. The fair value of these securities includes $2,208 of U.S. government subsidized securities collateralized by student loan obligations, with maturities greater than 10 years. We will not realize cash in respect of the principal amount of these securities until the issuer calls or restructures the security, the security reaches any scheduled maturity and is paid, or a buyer outside the auction process emerges. As of December 31, 2013, we have received all scheduled interest payments on these securities, which, in the event of auction failure, are reset according to the contractual terms in the governing instruments.
	The valuation of auction rate securities we hold is based on Level 3 unobservable inputs which consist of our internal analysis of (i) timing of expected future successful auctions or issuer calls of the securities, (ii) collateralization of underlying assets of the security and (iii) credit quality of the security. Significant increases (decreases) in the redemption period or discount rates would result in a significantly lower (higher) fair value measurement. In re-evaluating the valuation of these securities as of December 31, 2013, the temporary impairment amount, the duration of which is greater than 12 months, decreased from $260 at December 31, 2012, to $192, which is reflected as a part of accumulated other comprehensive loss on our accompanying Consolidated Balance Sheets and based on such re-evaluation, we believe that we have the ability to hold these securities until recovery of fair value. Due to the uncertainty related to the liquidity in the auction rate security market and therefore when individual positions may be liquidated, we have classified these auction rate securities as long-term assets on our accompanying Consolidated Balance Sheets. We continue to monitor markets for our investments and consider the impact, if any, of market conditions on the fair market value of our investments. We do not believe the carrying values of our investments are other than temporarily impaired and therefore expect the positions will eventually be liquidated without significant loss.
	The estimated fair value of the contingent consideration liability of $15.7 million represents future potential milestone payments to former MIP stockholders. The Company considers this liability a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. The estimated fair value was determined based on probability adjusted discounted cash flow and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs were the probabilities of achieving regulatory approval of the development projects and subsequent commercial success, and discount rates. Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement, respectively. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement, respectively. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the Consolidated Statements of Operations.
	The following table presents quantitative information pertaining to the fair value measurement of the Level 3 inputs:
		Fair Value			Valuation Technique		Unobservable Input		Range
		as of							(Weighted Average)
		31-Dec-13
	Asset:
	Auction Rate Securities	$	2,208		Discounted cash flow model		Redemption period		5 to 15 years
									(6 years)
							Discount rate			0.25% - 3.00%
										-1.55%
	Contingent consideration
	liability:
	Azedra commercialization	$	2,300		Probability adjusted discounted cash flow model		Probability of success			40%
							Period of milestone expected achievement			2017
							Discount rate			10%
	1404 commercialization	$	2,000		Probability adjusted discounted cash flow model		Probability of success			31%
							Period of milestone expected achievement			2018
							Discount rate			10%
	MIP-1095 commercialization	$	500		Probability adjusted discounted cash flow model		Probability of success			19%
							Period of milestone expected achievement			2021
							Discount rate			10%
	Net sales targets	$	10,900		Monte-Carlo simulation		Probability of success			19% - 40%
										-32.80%
							Period of milestone expected achievement			2018 - 2022
							Discount rate			12.50%
		Fair Value as of December 31, 2012			Valuation Technique		Unobservable Input		Range (Weighted Average)
	Asset:
	Auction Rate Securities	$	3,240		Discounted cash flow model		Redemption period		4 to 15 years
									(5.9 years)
							Discount rate			0.125% - 2.102% (0.71%)
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:
		Asset – Auction Rate Securities
		Fair Value Measurements Using Significant
		Unobservable Inputs
		(Level 3)
	Description	2013				2012
	Balance at beginning of period	$	3,240			$	3,332
	Transfers into Level 3		-				-
	Total realized/unrealized gains (losses)
	Included in net income (loss)		-				-
	Included in comprehensive income (loss)		68				8
	Settlements		(1,100	)			(100	)
Balance at end of period	$	2,208			$	3,240
Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date	$	-			$	-
	Liability – Contingent Consideration
	Fair Value Measurements Using Significant
	Unobservable Inputs
	(Level 3)
Description	2013				2012
Balance at beginning of period	$	-			$	-
Fair value of contingent consideration – acquisition of Molecular Insight		15,900				-
Fair value adjustment to contingent consideration included in net loss		(200	)			-
Balance at end of period	$	15,700			$	-
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$	(200	)		$	-
The following tables summarize the amortized cost basis, the aggregate fair value and gross unrealized holding gains and losses at December 31, 2013 and 2012:
	Amortized				Fair				Unrealized Holding
2013:00:00	Cost Basis				Value				Gains		(Losses)			Net
Maturities greater than ten years:
Auction rate securities	$	2,400			$	2,208			$	-	$	(192	)	$	(192	)
	$	2,400			$	2,208			$	-	$	(192	)	$	(192	)
	Amortized				Fair				Unrealized Holding
2012:00:00	Cost Basis				Value				Gains		(Losses)			Net
Maturities greater than ten years:
Auction rate securities	$	2,500			$	2,300			$	-	$	(200	)	$	(200	)
Investments without stated maturity dates:
Auction rate securities		1,000				940				-		(60	)		(60	)
	$	3,500			$	3,240			$	-	$	(260	)	$	(260	)
We compute the cost of its investments on a specific identification basis. Such cost includes the direct costs to acquire the securities, adjusted for the amortization of any discount or premium.
The following table shows the gross unrealized losses and fair value of our auction rate securities with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position, at December 31, 2013 and 2012.
2013:00:00	Less than 12 Months								12 Months or Greater					Total
Description of Securities	Fair Value				Unrealized Losses				Fair Value		Unrealized Losses			Fair Value			Unrealized Losses
Auction rate securities	$	-			$	-			$	2,208	$	(192	)	$	2,208		$	(192	)
Total	$	-			$	-			$	2,208	$	(192	)	$	2,208		$	(192	)
2012:00:00	Less than 12 Months								12 Months or Greater					Total
Description of Securities	Fair Value				Unrealized Losses				Fair Value		Unrealized Losses			Fair Value			Unrealized Losses
Auction rate securities	$	-			$	-			$	3,240	$	(260	)	$	3,240		$	(260	)
Total	$	-			$	-			$	3,240	$	(260	)	$	3,240		$	(260	)
Other-than-temporary impairment analysis on auction rate securities. The unrealized losses on our auction rate securities resulted from an internal analysis of timing of expected future successful auctions, collateralization of underlying assets of the security and credit quality of the security. At December 31, 2013 there was one and at December 31, 2012, there were two securities with a gross unrealized loss position of $192 and $260 ($2,208 and $3,240 of the total fair value), respectively.
The severity of the unrealized losses for auction rate securities at December 31, 2013 and 2012 was 8 percent below amortized cost, and the weighted average duration of the unrealized losses for these securities was 70 and 58 months, respectively.
We have evaluated our individual auction rate securities holdings for other-than-temporary impairment and determined that the unrealized losses as of December 31, 2013 and 2012 are attributable to uncertainty in the liquidity of the auction rate security market. Because we do not intend to sell these securities, and believe it is not more likely than not that we would be required to sell these securities before recovery of principal, we do not consider these securities to be other-than-temporarily impaired at December 31, 2013 and 2012.

Accounts_Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2013
Accounts Receivable [Abstract]	'
Accounts Receivable	'
	5. Accounts Receivable
	Our accounts receivable represent amounts due to Progenics from collaborators, royalties, research grants and the sales of research reagents and as of December 31, 2013 and 2012, consisted of the following:
		2013			2012
	Collaborators	$	12		$	6,125
	Royalties		2,862			781
	Research grants		-			12
	Other		12			19
			2,886			6,937
	Less, allowance for doubtful accounts		(7	)		-
	Total	$	2,879		$	6,937

Fixed_Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2013
Fixed Assets [Abstract]	'
Fixed Assets	'
	6. Fixed Assets
	Fixed assets as of December 31, 2013 and 2012 consisted of the following:
		2013			2012
	Computer equipment	$	2,234		$	2,166
	Machinery and equipment		7,091			8,031
	Furniture and fixtures		170			133
	Leasehold improvements		5,020			5,327
	Other		16			12
			14,531			15,669
	Less, accumulated depreciation and amortization		(12,118	)		(12,270	)
	Total	$	2,413		$	3,399
	At December 31, 2013 and 2012, $2.0 million and $2.6 million, respectively, of leasehold improvements, net were being amortized over periods of 8.5-10.8 years, under leases with terms through December 31, 2020.

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Accounts Payable and Accrued Expenses [Abstract]	'
Accounts Payable and Accrued Expenses	'
	7. Accounts Payable and Accrued Expenses
	The carrying value of our accounts payable and accrued expenses approximates fair value, as it represents amounts due to vendors and employees, which will be satisfied within one year. Accounts payable and accrued expenses as of December 31, 2013 and 2012, consisted of the following:
		2013		2012
	Accrued consulting and clinical trial costs	$	2,672	$	2,193
	Accrued payroll and related costs		2,123		1,552
	Restructuring accrual		-		813
	Legal and professional fees		608		774
	Accounts payable		793		229
	Other		316		79
	Total	$	6,512	$	5,640

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2013
Restructuring [Abstract]	'
Restructuring	'
	8. Restructuring
	We reduced headcount in the third and fourth quarters of 2011, resulting in a restructuring accrual of $1.3 million for severance and related benefits which were paid through August 2012. We incurred other exit and contract termination costs, including expenses related to a lease amendment and consolidation of employees within reduced facility space. We also reduced headcount in the third quarter of 2012, resulting in a restructuring accrual of $1.9 million which was paid through August 2013, and the first quarter of 2013, resulting in an approximately $1.5 million restructuring accrual which was paid through the end of 2013. During the second quarter of 2013, we incurred other exit and contract termination costs, including lease termination and amendment and consolidation expenses ($1,359).
	Activity in the restructuring accrual, which is included in accounts payable and accrued expenses in our Consolidated Balance Sheets, and in research and development and general and administrative expenses in the Consolidated Statements of Operations, is specified below.
		Severance and Related Benefits			Other Exit Costs			Contract Termination Costs			Total Restructuring Accrual
	Balance at December 31, 2010	$	-		$	-		$	-		$	-
	Additions, net		1,341			8			292			1,641
	Payments		(770	)		(2	)		(138	)		(910	)
	Balance at December 31, 2011		571			6			154			731
	Additions, net		1,905			184			3			2,092
	Payments		(1,663	)		(190	)		(157	)		(2,010	)
	Balance at December 31, 2012		813			-			-			813
	Additions, net		1,492			15			1,359			2,866
	Payments		(2,305	)		(15	)		(1,359	)		(3,679	)
	Balance at December 31, 2013	$	-		$	-		$	-		$	-

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	9. Stockholders' Equity
	We are authorized to issue 160.0 million shares of Common Stock, par value $.0013, and 20.0 million shares of preferred stock, par value $.001. The Board of Directors has the authority to issue common and preferred shares, in series, with rights and privileges as determined by the Board of Directors. In July 2013, we completed a public offering of 9,775 shares of common stock, with net proceeds of approximately $40.1 million.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	10. Commitments and Contingencies
	a. Operating Leases
	As of December 31, 2013, we leased office, manufacturing and laboratory space, under lease agreements expiring in December 2020.
	Rental payments are recognized as rent expense on a straight-line basis over the term of the lease. In addition to rents due under these agreements, we are obligated to pay additional facilities charges, including utilities, taxes and operating expenses.
	As of December 31, 2013, future minimum annual payments under all operating lease agreements are as follows:
	Years ending December 31,	Minimum
		Annual Payments
	2014	$	1,841
	2015		1,887
	2016		1,934
	2017		1,983
	2018		2,032
	Thereafter		4,218
	Total	$	13,895
	Rental expense totaled approximately $3,548, $2,074 and $3,475 for 2013, 2012 and 2011, respectively. For 2013 and 2012, amounts paid exceeded rent expense by $164 and $419, respectively, due to the recognition of lease incentives. For 2011, we recognized rent expense in excess of amounts paid of $63, due to the recognition of escalation clauses and lease incentives. Additional facility charges, including utilities, taxes and operating expenses, for 2013, 2012 and 2011 were approximately $2,330, $2,845 and $4,033, respectively.
	b. Licensing, Service and Supply Agreements
	Progenics and its subsidiaries have entered into intellectual property-based license and service agreements in connection with product development programs, and have recognized milestone, license and sublicense fees and supply costs, included in research and development expenses, totaling approximately $567, $1,170 and $578 during the last three years, respectively.
		Paid from inception to December 31, 2013		Future (1)		Terms
				Commitments
	Progenics agreements with:
	Lonza Sales AG	$	909	$	824	Annual license fee payments, milestones and royalties, as applicable, in respect of oncology and other products.
	PSMA LLC agreements with:
	Seattle Genetics, Inc.		4,400		13,900	Milestone and periodic maintenance payments to use ADC technology to link chemotherapeutic agents to monoclonal antibodies that target prostate specific membrane antigen. ADC technology is based in part on technology licensed by SGI from third parties.
	Amgen Fremont, Inc. (formerly Abgenix)		1,350		5,750	Milestones and royalties to use XenoMouse® technology for generating fully human antibodies to PSMA LLC's PSMA antigen.
	Former member of PSMA LLC		278		52,188	Annual minimum royalty payments and milestones to use technology related to PSMA.
		Paid from acquisition date to December 31, 2013		Future (1)		Terms
				Commitments
	MIP agreements with:
	University of Zurich and the Paul Scherrer Institute		65		1,225	Annual maintenance and license fee payments, milestones and royalties in respect of licensed technology related to 1404.
	University of Western Ontario		4		374	Annual minimum royalty, administration and milestone payments in respect of licensed technology related to Azedra.
	Novartis Pharma AG and other interests		-		4,600	Milestone and royalty payments in respect of licensed technology related to Onalta.
	Bayer Schering Pharma AG		-		9,000	Milestone and royalty payments in respect of licensed technology related to a MIP asset.
	(1) Amounts based on known contractual obligations as specified in the respective license agreements, which are dependent on the achievement or occurrence of future milestones or events and exclude amounts for royalties which are dependent on future sales and are unknown.
	We are seeking to out-license or terminate non-germane Molecular Insight licenses and service agreements, as to which we have paid $216 through December 31, 2013, and have future commitments of $3,453, subject to occurrence of future milestones or events.
	c. Consulting Agreements
	As part of our research and development efforts, we have from time to time entered into consulting agreements with external scientific specialists. These agreements contain various terms and provisions, including fees to be paid by us and royalties, in the event of future sales, and milestone payments, upon achievement of defined events, payable by us. Certain of these scientists are advisors to Progenics, and some have purchased our Common Stock or received stock options which are subject to vesting provisions. We have recognized expenses with regard to the consulting agreements of $39, $8 and $27 for 2013, 2012 and 2011, respectively. Those expenses include the fair value of stock options granted during 2013 and 2011, which were fully vested at grant date, of approximately $7 and $11, respectively. Such amounts of fair value are included in research and development expense for each year presented (see Note 11).
	d. Retirement Agreement
	On March 14, 2012, Progenics and company founder Paul J. Maddon entered into an agreement providing for his retirement as Chief Science Officer. In connection with Dr. Maddon's retirement and termination of his employment agreement, Progenics agreed to pay him an amount equal to $1,789 and provide other benefits under the agreement.
	e. Related Party Agreement
	In December 2012, Progenics entered into a financial advisory agreement with MTS Health Partners, L.P., of which the Company's Board Chair is a Senior Managing Director and partner, on customary terms and conditions, whereby, in 2013, MTS has received monthly retainers totaling $55 during the term of the agreement and $300 for MTS' services in connection with the Molecular Insight acquisition described in Note 2. This agreement was terminated in June 2013.
	f. Legal Proceedings
	Progenics is a party to a proceeding brought by a former employee complaining that the Company violated the anti-retaliation provisions of the federal Sarbanes-Oxley law by terminating the former employee. The Company believes the former employee's claims are without merit and is contesting the matter vigorously. The federal District Court hearing the case issued in July 2013 an order denying our motion for summary judgment dismissing the former employee's complaint, making it likely that the proceeding will continue to trial. Given the inherent uncertainty attendant to the proceeding, it is not possible at this time to estimate the likelihood or potential magnitude of any outcome, and we have accordingly not recorded any associated liability in these Consolidated Financial Statements.
	Progenics in October 2013 commenced an arbitration with Ono under the provisions of the parties' License Agreement, following a communication from Ono that it has determined to discontinue development of subcutaneous Relistor in Japan because of "commercial concerns" that Ono contends would permit it to cease development and terminate the Agreement. Under our Agreement with Ono, Ono may cease development of subcutaneous Relistor only if it terminates the License Agreement, which it may do unilaterally only if Progenics is in material default. Progenics is not in default under the Agreement, and Ono has neither asserted that Progenics is, nor terminated the Agreement.

ShareBased_Payment_Arrangement

Share-Based Payment Arrangements	12 Months Ended
	Dec. 31, 2013
Share-Based Payment Arrangements [Abstract]	'
Share-Based Payment Arrangements	'
	11. Share-Based Payment Arrangements
	Our share-based compensation to employees includes non-qualified stock options, restricted stock and shares issued under our Purchase Plans, which are compensatory under ASC 718 Compensation – Stock Compensation. During the second quarter of 2011, we accelerated the vesting of outstanding awards to non-management employees in connection with a change in program eligibility and termination of the Company's employee stock purchase plans. We account for share-based compensation to non-employees, including non-qualified stock options and restricted stock, in accordance with ASC 505 Equity.
	Compensation cost for share-based awards will be recognized in our financial statements over the related requisite service periods; usually the vesting periods for awards with a service condition. We have made an accounting policy decision to use the straight-line method of attribution of compensation expense, under which the grant date fair value of share-based awards will be recognized on a straight-line basis over the total requisite service period for the total award.
	We have adopted two stock incentive plans, the 1996 Amended Stock Incentive Plan (terminated in 2006) and the 2005 Stock Incentive Plan. Under these Plans as amended, up to 5,000 and 8,450 shares of common stock, respectively, have been reserved for the issuance of awards to employees, consultants, directors and other individuals who render services to Progenics (collectively, Awardees). The Plans contain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment as defined. Each Plan provides for the Board or Committee to grant to Awardees stock options, stock appreciation rights, restricted stock, performance awards or phantom stock, as defined (collectively, Awards). The Committee is also authorized to determine the term and vesting of each Award and the Committee may in its discretion accelerate the vesting of an Award at any time. Stock options granted under the Plans generally vest pro rata over three to five years and have terms of ten years. Restricted stock issued under either Plan generally vested annually over three to five years, unless specified otherwise by the Committee. The exercise price of outstanding non-qualified stock options is usually equal to the fair value of our common stock on the date of grant. The exercise price of non-qualified stock options granted from the 2005 Plan and incentive stock options (ISO) granted from the Plans may not be lower than the fair value of our common stock on the dates of grant. At December 31, 2013, 2012 and 2011, all outstanding stock options were non-qualified options. The 2005 Plan will terminate in April 2015; options granted before termination of the Plans will continue under the respective Plans until exercised, cancelled or expired.
	We apply a forfeiture rate to the number of unvested awards in each reporting period in order to estimate the number of awards that are expected to vest. Estimated forfeiture rates are based upon historical data on vesting behavior of employees. We adjust the total amount of compensation cost recognized for each award, in the period in which each award vests, to reflect the actual forfeitures related to that award. Changes in our estimated forfeiture rate will result in changes in the rate at which compensation cost for an award is recognized over its vesting period.
	Under ASC 718 Compensation – Stock Compensation, the fair value of each non-qualified stock option award is estimated on the date of grant using the Black-Scholes option pricing model, which requires input assumptions noted in the following table. Ranges of assumptions for inputs are disclosed where the value of such assumptions varied during the related period. Historical volatilities are based upon daily quoted market prices of our common stock on The NASDAQ Stock Market LLC over a period equal to the expected term of the related equity instruments. We rely only on historical volatility since it provides the most reliable indication of future volatility. Future volatility is expected to be consistent with historical; historical volatility is calculated using a simple average calculation; historical data is available for the length of the option's expected term and a sufficient number of price observations are used consistently. Since our stock options are not traded on a public market, we do not use implied volatility. For 2013, 2012 and 2011 our expected term was calculated based upon historical data related to exercise and post-termination cancellation activity; accordingly, for grants issued to employees and directors and officers (excluding our former CEO in 2011), we are using expected terms of 5.3 and 7.4 years, 5.4 and 7.4 years and 5.3 and 7.4 years, respectively. The expected term of stock options granted to our former CEO in 2011 was calculated separately from stock options granted to employees and directors and officers, and was 8 years for 2011. The expected term for options granted to non-employees was also calculated separately from stock options granted to employees and directors and officers and was ten years, which is the contractual term of those options. We have never paid dividends and do not expect to pay dividends in the future. Therefore, our dividend rate is zero. The risk-free rate for periods within the expected term of the options is based on the U.S. Treasury yield curve in effect at the time of grant. The following table presents assumptions used in computing the fair value of option grants during 2013, 2012 and 2011:
		2013			2012			2011
	Expected volatility		73% – 90	%		70% – 85	%		68% – 78	%
	Expected dividends	Zero			Zero			Zero
	Expected term (years)		5.3 – 10			5.3 – 10			5.3 – 10
	Weighted average expected term (years)		5.96			6.11			6.17
	Risk-free rate		0.76% – 2.83	%		0.57% – 1.71	%		0.77% – 2.97	%
	A summary of option activity under the Plans as of December 31, 2013 and changes during the year then ended is presented below:
	Options	Shares			Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Yr.)			Aggregate Intrinsic Value
	Outstanding at January 1, 2013		5,366		$	12.27
	Granted		1,018			5.13
	Exercised		(14	)		5.08
	Forfeited		(608	)		10.63
	Expired		(463	)		14.7
	Outstanding at December 31, 2013		5,299			10.89			5.82		$	304
	Exercisable at December 31, 2013		3,875		$	12.45			4.86		$	118
	The weighted average grant-date fair value of options granted under the Plans during 2013, 2012 and 2011 was $3.74, $6.38 and $5.51, respectively. The total intrinsic value of options exercised during 2013, 2012 and 2011 was $11, $174 and $345, respectively.
	The options granted under the Plans, described above, include non-qualified stock options granted to our former CEO on July 3, 2006. For the 2006 award, the requisite service period is the shortest of the explicit or implied service periods and the explicit service period for this award is nine years and 11 months from the grant date. On July 1, 2011 and March 1, 2012, we granted option awards to our CEO which vests on the basis of the achievement of specified performance-based milestones. The options have exercise prices equal to the closing price of our common stock on the dates of grant. The awards are valued using the Black-Scholes option pricing model. The expense related to the grants with performance and market-based milestones will be recognized over the shortest estimated time for the achievement of the performance or market conditions. The awards will not vest unless one of the milestones is achieved or the market condition is met. Changes in the estimate of probability of achievement of any performance or market condition will be reflected in compensation expense of the period of change and future periods affected by the change.
	At December 31, 2013, the estimated requisite service periods for the 2006, 2011 and 2012 awards, described above, were 2.5, 1.0 and 1.0 years, respectively. For 2013, 2012 and 2011, the total compensation expense recognized for the performance-based options was $0.1 million, $2.0 million and $0.4 million, respectively.
	A summary of the status of our outstanding restricted stock awarded under the Plans as of December 31, 2013 and changes during the year then ended is presented below:
	Restricted Stock Awards	Shares			Weighted Average Grant-Date
					Fair Value
	Nonvested at January 1, 2013		28		$	5.35
	Granted		-			-
	Vested		(27	)		5.35
	Forfeited		(1	)		5.35
	Nonvested at December 31, 2013		-		$	-
	Two employee stock purchase plans (the Purchase Plans), the 1998 Employee Stock Purchase Plan (the Qualified Plan) and the 1998 Non-Qualified Employee Purchase Plan (the Non-Qualified Plan), as amended, provided for the issuance of up to 4,400 and 1,100 shares of common stock, respectively. Issuances of common stock under the Purchase Plans, terminated by the Company during the second quarter of 2011, provided for the grant to all employees of options to use an amount equal to 25% of their quarterly compensation, as such percentage was determined by the Board of Directors prior to the date of grant, to purchase shares of our common stock at a price per share equal to the lesser of the fair market value of the common stock on the date of grant or 85% of the fair market value on the date of exercise. Options were granted automatically on the first day of each fiscal quarter and expired six months after the date of grant. The Qualified Plan was not available to employees owning more than five percent of the common stock and imposed certain other quarterly limitations on option grants. Options under the Non-Qualified Plan were granted to the extent that option grants were restricted under the Qualified Plan.
	The fair value of shares purchased under the Purchase Plans was estimated on the date of grant in accordance with ASC 718 Compensation – Stock Compensation, via the same option valuation model used for options granted under the Plans, but with the following assumptions during 2011:
		2011
	Expected volatility		43% – 51	%
	Expected dividends	zero
	Expected term	6 months
	Risk-free rate		0.06% – 0.22	%
	Purchases of common stock under the Purchase Plans during 2011 are summarized as follows:
		Qualified Plan									Non-Qualified Plan
		Shares Purchased			Price Range			Weighted			Shares Purchased		Price Range		Weighted
								Average Grant-Date Fair Value							Average Grant-Date Fair Value
	2011		428		$	4.62 – $5.65		$	0.88			162	$	4.62 – $5.65	$	0.84
	The total compensation expense of shares, granted to both employees and non-employees, under all of our share-based payment arrangements that was recognized in operations during 2013, 2012 and 2011 was:
		2013			2012			2011
	Recognized as:
	Research and Development	$	2,524		$	4,568		$	4,499
	General and Administrative		1,022			1,968			1,863
	Total	$	3,546		$	6,536		$	6,362
	No tax benefit was recognized related to such compensation cost because of the Company's net operating losses and the related deferred tax assets were fully offset by valuation allowance. Accordingly, no amounts related to windfall tax benefits have been reported in cash flows from operations or cash flows from financing activities for the periods presented.
	As of December 31, 2013, there was $4.4 million of total unrecognized compensation cost related to non-vested stock options under the 1996 and 2005 Plans. Those costs are expected to be recognized over a weighted average period of 2.1 years. Cash received from exercises under all share-based payment arrangements for 2013 was $0.1 million. We issue new shares of our common stock upon share option exercises.
	In applying the treasury stock method for the calculation of diluted EPS, amounts of unrecognized compensation expense and windfall tax benefits are required to be included in the assumed proceeds in the denominator of the diluted EPS calculation unless they are anti-dilutive. We incurred net losses for 2013 and 2012 and, therefore, such amounts have not been included in the calculations for those periods since they would be anti-dilutive. As a result, basic and diluted EPS are the same for the 2013 and 2012 periods. We reported net income for 2011 and included the dilutive effect of unrecognized compensation expense in the assumed proceeds in the denominator of the diluted EPS calculation. We have made an accounting policy decision to calculate windfall tax benefits/shortfalls, for purposes of diluted EPS calculation, excluding the impact of deferred tax assets. This policy decision will apply when we have net income and windfall tax benefits/shortfalls are realizable.

Employee_Savings_Plan

Employee Savings Plan	12 Months Ended
	Dec. 31, 2013
Employee Savings Plan [Abstract]	'
Employee Savings Plan	'
	12. Employee Savings Plan
	The terms of the amended and restated Progenics Pharmaceuticals 401(k) Plan (the Amended Plan), among other things, allow eligible employees to participate in the Amended Plan by electing to contribute to the Amended Plan a percentage of their compensation to be set aside to pay their future retirement benefits. During the three years ended December 31, 2013, we matched 50% of those employee contributions that are equal to 5%-8% of compensation and are made by eligible employees to the Amended Plan (the Matching Contribution). In addition, we may also make a discretionary contribution each year on behalf of all participants who are non-highly compensated employees. We made Matching Contributions of approximately $330, $535 and $597 to the Amended Plan for 2013, 2012 and 2011, respectively. No discretionary contributions were made during those years.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	13. Income Taxes
	We account for income taxes using the liability method in accordance with ASC 740 Income Taxes. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
	There is no provision or benefit for federal or state income taxes for 2013, 2012 and 2011, other than $0.4 million income tax benefit in 2013, resulting from the change in the temporary difference between carrying amounts of in-process research and development assets for financial reporting purposes and the amounts used for income tax purposes. We have completed a calculation through March 31, 2011, under Internal Revenue Code Section 382, the results of which indicate that past ownership changes will limit utilization of NOLs in the future. Ownership changes subsequent to March 31, 2011, may further limit the future utilization of net operating loss and tax credit carry-forwards as defined by the federal and state tax codes.
	Deferred tax assets and liabilities as of December 31, 2013 and 2012, consisted of the following:
		2013			2012
	Deferred tax assets:
	Depreciation and amortization	$	6,165		$	6,497
	R&E tax credit carry-forwards		5,129			11,843
	NYS investment tax credit carry-forwards		1,095			1,084
	AMT credit carry-forwards		211			211
	Net operating loss carry-forwards		190,263			112,966
	Capitalized research and development expenditures		25,231			30,884
	Stock compensation		13,826			14,436
	Other items		1,097			2,193
	Total gross deferred tax assets		243,017			180,114
	Less: Valuation allowance		(243,017	)		(178,045	)
	Deferred tax assets		-			2,069
	Deferred tax liability - current		-			(2,069	)
	Deferred tax liability – long term		(12,321	)		-
	Net deferred tax liability	$	(12,321	)	$	-
	We do not recognize deferred tax assets considering our history of taxable losses and the uncertainty regarding our ability to generate sufficient taxable income in the future to utilize these deferred tax assets. For 2013 and 2012, we incurred net losses for tax purposes. For 2011, we had income for tax purposes and such amount was offset completely by our available net operating loss carry-forwards. We recognized a full tax valuation against deferred taxes at December 31, 2013. In 2012, we recognized deferred income tax assets, net of a valuation allowance, of $2,069 ($17 in current assets and $2,052 in non-current assets) and in 2013 and 2012 we recognized deferred income tax liabilities of $12,321 and $2,069, respectively to reflect the net tax effects of temporary differences between the carrying amounts of certain assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The recognition of these deferred income tax assets and liabilities had no effect on our net loss for 2012, however, it resulted in $362 income tax benefit for 2013.
	The following is a reconciliation of income taxes computed at the Federal statutory income tax rate to the actual effective income tax provision during 2013, 2012 and 2011:
		2013			2012			2011
	U.S. Federal statutory rate		(34.0	)%		(35.0	)%		35	%
	State income taxes, net of Federal benefit		(4.9	)		(5.4	)		8
	Research and experimental tax credit		(3.6	)		-			(4.1	)
	Change in valuation allowance		11.4			34.7			(22.6	)
	Effect of federal tax rate bracket change on valuation allowance		8.7			-			(34.8	)
	Equity compensation		3.1			4.2			17
	Investment tax credit		(0.1	)		-			(0.1	)
	NOL expiration – Section 382		18.6			-			-
	Other		-			1.5			1.6
	Income tax provision (benefit)		(0.8	)%		0	%		0	%
	As of December 31, 2013, we had available, for tax return purposes, unused federal NOLs of approximately $513.8 million, which will expire in various years from 2018 to 2033, $18.2 million of which were generated from deductions post January 1, 2006 that, when realized, will reduce taxes payable and will increase paid-in-capital and are not reflected in our deferred tax assets above. Additionally, $11.2 million of the valuation allowance relates to NOLs attributable to excess tax deductions for equity compensation pre January 1, 2006. When realized this will also be reflected as an increase to paid-in-capital. Also, we had available, for tax return purposes, unused state NOLs of approximately $453.1 million, which will expire in various years from 2019 to 2033.
	We have reviewed our nexus in various tax jurisdictions and our tax positions related to all open tax years for events that could change the status of our ASC 740 Income Taxes liability, if any, or require an additional liability to be recorded. During 2013, 2012 and 2011, we had no unrecognized tax benefits resulting from tax positions during a prior or current period, settlements with taxing authorities or the expiration of the applicable statute of limitations, except for the $0.4 million income tax benefit recognized in 2013, resulting from the change in the difference between carrying amounts of in-process research and development assets for financial reporting purposes and the amounts used for income tax purposes. We have not, as of yet, conducted a study of our research and development credit carry-forwards. Such a study might result in an adjustment to our research and development credit carry-forwards, but until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position under ASC 740-10. A full valuation allowance has been provided against the Company's research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the statements of operations and comprehensive loss if an adjustment was required.
	As of December 31, 2013, we are subject to federal and state income tax in the U.S. Open tax years relate to years in which unused net operating losses were generated or, if used, for which the statute of limitation for examination by taxing authorities has not expired. Our open tax years extend back to 1996. No amounts of interest or penalties were recognized in our Consolidated Statements of Operations or Consolidated Balance Sheets as of and for 2013, 2012 and 2011.
	Our research and experimental (R&E) tax credit carry-forwards of approximately $5.1 million at December 31, 2013 expire in various years from 2018 to 2033. During 2013, research and experimental tax credit carry-forwards of approximately $20 expired. The American Taxpayer Relief Act of 2012, enacted on January 2, 2013, retroactively reinstated the federal research and development credit for 2012 and extended these credits through 2013.
	As of December 31, 2013, we have not recognized any liability for uncertain tax positions, because of our full valuation allowance. We will recognize interest and penalties related to these positions, should such costs be assessed. As of December 31, 2013, we have not recognized interest and penalties. The recognition of unrecognized tax benefits would not affect our effective tax rate because the tax benefit would be offset by an increase in our valuation allowance.
	The following is a tabular reconciliation of the total amounts of unrecognized tax benefits for the year ended December 31, 2013.
		2013
	Beginning uncertain tax benefits	$	2,661
	Current year - increases		-
	Current year - decreases		-
	Settlements		-
	Expired statuses		-
	Ending uncertain tax benefits	$	2,661

Net_Income_Loss_Per_Share

Net Income (Loss) Per Share	12 Months Ended
	Dec. 31, 2013
Net Income (Loss) Per Share [Abstract]	'
Net Income (Loss) Per Share	'
	14. Net Income (Loss) Per Share
	Our basic net (loss) income per share amounts have been computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period. For 2013 and 2012, we reported net losses and, therefore, potential common shares were not included since such inclusion would have been anti-dilutive. For 2011, we reported net income, and the computation of diluted earnings per share is based upon the weighted-average number of our common shares and dilutive effect, determined using the treasury stock method, of potential common shares outstanding. As of December 31, 2012 and 2011, our 28 and 98, respectively, shares of unvested restricted stock with non-forfeitable rights to dividends were outstanding; all such shares were vested at the end of December 31, 2013. The allocation of 2012 net losses and the 2011 net income to these participating securities pursuant to the two-class method is not material to both basic and diluted earnings per share. The calculations of net loss per share, basic and diluted, are as follows:
		Net (Loss) Income			Weighted Average		Per Share
		(Numerator)			Common Shares		Amount
					(Denominator)
	2013:00:00
	Basic and diluted	$	(42,572	)		55,798	$	(0.76	)
	2012:00:00
	Basic and diluted	$	(35,431	)		34,754	$	(1.02	)
	2011:00:00
	Basic	$	10,381			33,375	$	0.31
	Dilutive effect of stock options		-			66
	Dilutive effect of restricted stock		-			53
	Diluted	$	10,381			33,494	$	0.31
	During 2013, 2012 and 2011, anti-dilutive common shares excluded from diluted per share amounts consist of the following:
		2013					2012					2011
		Weighted			Weighted		Weighted			Weighted		Weighted		Weighted
		Average			Average		Average			Average		Average		Average
		Number			Exercise Price		Number			Exercise Price		Number		Exercise Price
	Options		5,969		$	11.54		5,947		$	12.32		4,543	$	14.92
	Restricted stock		-					60					45
	Total		5,969					6,007					4,588

Unaudited_Quarterly_Results_un

Unaudited Quarterly Results (unaudited)	12 Months Ended
	Dec. 31, 2013
Unaudited Quarterly Results (unaudited) [Abstract]	'
Unaudited Quarterly Results (unaudited)	'
	15. Unaudited Quarterly Results (unaudited)
	Summarized quarterly financial data during 2013 and 2012 are as follows:
			2013 Quarter Ended
			31-Mar			30-Jun			30-Sep			31-Dec
	Revenues		$	2,226		$	1,801		$	867		$	2,968
	Net loss			(11,258	)		(12,263	)		(10,500	)		(8,551	)
	Net loss per share - basic and diluted			(0.22	)		(0.24	)		(0.17	)		(0.14	)
			2012 Quarter Ended
			31-Mar			30-Jun			30-Sep			31-Dec
	Revenues (1)		$	2,226		$	1,820		$	1,117		$	8,885
	Net loss			(13,086	)		(10,720	)		(11,301	)		(324	)
	Net loss per share - basic and diluted			(0.39	)		(0.32	)		(0.33	)		(0.01	)
	_______________
	-1	Revenues in the fourth quarter of 2012 include $5.0 million and $2.8 million from the MedImmune and CytoDyn Agreements, respectively.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	16. Subsequent Event
	During the first quarter of 2014, we established a $150 million shelf registration statement (inclusive of approximately $31.7 million of availability under a superseded registration) which we used for our recent underwritten public offering of 8.75 million shares of common stock at a public offering price of $4.60 per share, resulting in net proceeds of approximately $37.5 million.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Schedule II - Valuation and Qualifying Accounts [Abstract]	'
Schedule II - Valuation and Qualifying Accounts [Text Block]	'
	Allowance for Doubtful Accounts
	Year ended December 31,	Beginning Balance		Additions		Deductions		Ending Balance
				Charged to General and administrative expenses		Accounts Written Off During Period
	(in thousands)
	2013	$	-	$	7	$	-	$	7

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The consolidated financial statements have been prepared on the basis of accounting principles generally accepted in the U.S. (GAAP). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, the Company evaluates its estimates, including but not limited to those related to collectability of receivables, intangible assets and contingencies. As additional information becomes available or actual amounts become determinable, the recorded estimates are revised and reflected in the operating results. Actual results could differ from those estimates.
Consolidation	'
	Consolidation
	The consolidated financial statements include the accounts of Progenics and PSMA LLC, as of and for the years ended December 31, 2013, 2012 and 2011 and Molecular from January 18, 2013, the date we acquired this subsidiary. Inter-company transactions have been eliminated in consolidation.
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue from all sources based on the provisions of the SEC's Staff Accounting Bulletin (SAB) No. 104 (SAB 104) and ASC 605 Revenue Recognition. Under ASC 605, delivered items are separate units of accounting, provided (i) the delivered items have value to a collaborator on a stand-alone basis, and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered items is considered probable and substantially in our control. A separate update to ASC 605 provides guidance on the criteria that should be met when determining whether the milestone method of revenue recognition is appropriate.
	If we are involved in a steering or other committee as part of a multiple-deliverable arrangement, we assess whether our involvement constitutes a performance obligation or a right to participate. For those committees that are deemed obligations, we will evaluate our participation along with other obligations in the arrangement and will attribute revenue to our participation through the period of our committee responsibilities. We recognize revenue for payments that are contingent upon performance solely by our collaborator immediately upon the achievement of the defined event if we have no related performance obligations. Reimbursement of costs is recognized as revenue provided the provisions of ASC 605 are met, the amounts are determinable and collection of the related receivable is reasonably assured.
	Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Amounts not expected to be recognized within one year of the balance sheet date are classified as long-term. The estimate of the classification of deferred revenue as short- or long-term is based upon the period in which we expect to perform joint committee services.
	Royalty revenue is recognized in the period the sales occur, provided the royalty amounts are fixed or determinable, collection of the related receivable is reasonably assured and we have no remaining performance obligations under the arrangement providing for the royalty.
	During the past three years, we also recognized revenue from sales of research reagents and from government research grants, awarded to us by the National Institutes of Health (NIH), which we used in proprietary research programs. NIH grant revenue is recognized as efforts are expended and as related program costs are incurred. We performed work under the NIH grants on a best-effort basis.
	Under Molecular's 2013 license of certain research, development and commercialization rights to Onalta™, we received a $0.2 million in upfront payment and are eligible for future milestone and royalty payments. In consideration for the upfront payment, we have delivered relevant know-how (including patent rights), inventory and non-reimbursable services.
	In the fourth quarter of 2012, we out-licensed our C. difficile program to MedImmune, LLC for a $5.0 million upfront payment, and the right to receive potential future milestone and royalty payments. In consideration for the upfront payment, we have delivered relevant know-how (including patent rights) and non-reimbursable services.
	Under our 2012 agreement with CytoDyn Inc. for our PRO 140 program, we received $3.5 million payment and are eligible for future milestone and royalty payments. In consideration for the upfront payment, we have delivered relevant know-how (including patent rights), inventory and non-reimbursable services.
	Under our license agreement, Salix is responsible for further developing and commercializing Relistor worldwide other than Japan. In consideration of the $60.0 million upfront payment from Salix, we have granted Salix an exclusive license of relevant know-how, patent rights and technology, assigned relevant third-party contracts, and served on joint committees provided for in the License Agreement through end of 2013.
	These deliverables, which have stand-alone value and represent separate units of accounting, include (i) the exclusive license which was delivered for revenue recognition purposes during the 2011 second quarter, (ii) performing reimbursable development services at Salix's direction during the 2011 second quarter, the period in which we and Salix finalized the development plan, and (iii) joint committee services, which have been performed through 2013. We determined that the license has stand-alone value as the license was delivered to Salix for revenue recognition purposes in the second quarter of 2011 and Salix is responsible for continuing research and development.
	We developed a best estimate of selling price for each deliverable as vendor-specific objective evidence and third-party evidence was not available. We allocated the best estimate of selling price, on a relative basis, to each of the three units of accounting as the $60.0 million upfront payment was the only payment from Salix which was fixed and determinable at the inception of the arrangement. As a result, $58.4 million, $1.1 million and $0.5 million was allocated to the license, reimbursable development services and our participation in the joint committees as provided in the License Agreement, respectively. We recognized $58.4 million for the license and relevant know-how, patent rights and technology and $1.1 million for the reimbursable development services, respectively, during the second quarter of 2011, the period in which we delivered these items and performed the development services. We recognized $0.2 million, $0.2 million and $59.6 million during 2013, 2012 and 2011, respectively. At December 31, 2012, the remaining deferred revenue of $0.2 million, pertaining to joint committee services, was recognized as collaboration revenue in 2013, as such activities were performed.
	Ono is responsible for developing and commercializing subcutaneous Relistor in Japan, including conducting the clinical development necessary to support regulatory marketing approval. Ono will own the filings and approvals related to subcutaneous Relistor in Japan. In addition to the $15.0 million upfront payment from Ono, we are entitled to receive up to an additional $20.0 million, payable upon achievement by Ono of its development milestones. Ono is also obligated to pay to us royalties and commercialization milestones on sales by Ono of subcutaneous Relistor in Japan. Ono has the option to acquire from us the rights to develop and commercialize in Japan other formulations of Relistor, including intravenous and oral forms, on terms to be negotiated separately. Ono may request us to perform activities related to its development and commercialization responsibilities, beyond our participation in joint committees and specified technology transfer-related tasks, at its expense payable at the time we perform such services. Revenue earned from activities we perform for Ono is recorded in collaboration revenue.  See Note 10.
Research and Development Expenses	'
	Research and Development Expenses
	Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, maintenance of research equipment, costs related to research collaboration and licensing agreements, the purchase of in-process research and development, the cost of services provided by outside contractors, including services related to our clinical trials, the full cost of manufacturing drug for use in research, pre-clinical development and clinical trials. All costs associated with research and development are expensed as incurred.
	At each period end, we evaluate the accrued expense balance related to these activities based upon information received from the suppliers and estimated progress towards completion of the research or development objectives to ensure that the balance is reasonably stated. Such estimates are subject to change as additional information becomes available.
Use of Estimates	'
	Use of Estimates
	Significant estimates include useful lives of fixed assets, the periods over which certain revenues and expenses will be recognized, including collaboration revenue recognized from non-refundable up-front licensing payments and expense recognition of certain clinical trial costs which are included in research and development expenses, the amount of non-cash compensation costs related to share-based payments to employees and non-employees and the periods over which those costs are expensed, the likelihood of realization of deferred tax assets and the assumptions used in the valuations of in-process research and development and contingent consideration liability.
Patents	'
	Patents
	As a result of research and development efforts conducted by us, we have applied, or are applying, for a number of patents to protect proprietary inventions. All costs associated with patents are expensed as incurred.
Net (Loss) Income Per Share	'
	Net (Loss) Income Per Share
	We prepare earnings per share (EPS) data in accordance with ASC 260 Earnings Per Share. Basic net (loss) income per share amounts have been computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period. For 2013 and 2012, we reported net losses and, therefore, potential common shares, amounts of unrecognized compensation expense and windfall tax benefits have been excluded from diluted net loss per share since they would be anti-dilutive. For 2011, we reported net income, and the computation of diluted earnings per share is based upon the weighted-average number of our common shares and dilutive effect, determined using the treasury stock method, of potential common shares outstanding including amounts of unrecognized compensation expense. As of December 31, 2012 and 2011, 28 and 98, respectively, shares of unvested restricted stock outstanding have non-forfeitable rights to dividends; all such shares were vested at the end of December 31, 2013. The allocation of 2013 and 2012 net losses and the 2011 net income to these participating securities pursuant to the two-class method is not material to both basic and diluted earnings per share.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk
	Financial instruments which potentially subject Progenics to concentrations of risk consist principally of cash, cash equivalents, auction rate securities and receivables. We invest our excess cash in money market funds. We have established guidelines that relate to credit quality, diversification and maturity and that limit exposure to any one issue of securities. We hold no collateral for these financial instruments.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	We consider all highly liquid investments which have maturities of three months or less, when acquired, to be cash equivalents. The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value. Cash and cash equivalents subject us to concentrations of credit risk. At December 31, 2013 and 2012, we have invested approximately $60,364 and $56,224, respectively, in cash equivalents in the form of money market funds with one major investment company and held approximately $4,898 and $2,614, respectively, in a single commercial bank.
Receivables, Policy [Policy Text Block]	'
	Accounts Receivable
	We estimate the level of accounts receivable which ultimately will be uncollectable based on a review of specific receivable balances, industry experience and the current economic environment. We reserve for affected accounts receivable an allowance for doubtful accounts, which at December 31, 2013 was $7.
Auction Rate Securities	'
	Auction Rate Securities
	In accordance with ASC 320 Investments – Debt and Equity Securities, investments are classified as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in comprehensive (loss) income. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income or expense. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. In computing realized gains and losses, we compute the cost of its investments on a specific identification basis. Such cost includes the direct costs to acquire the securities, adjusted for the amortization of any discount or premium. The fair value of auction rate securities has been estimated based on a three-level hierarchy for fair value measurements. Interest and dividends on securities classified as available-for-sale are included in interest income (see Note 4).
	At December 31, 2013 and 2012, our investment in auction rate securities (recorded as long-term assets in the Consolidated Balance Sheets) amounted to $2,208 and $3,240, respectively. Valuation of securities is subject to uncertainties that are difficult to predict, such as changes to credit ratings of the securities and/or the underlying assets supporting them, default rates applicable to the underlying assets, underlying collateral value, discount rates, counterparty risk, ongoing strength and quality of market credit and liquidity and general economic and market conditions. The valuation of the auction rate securities we hold is based on an internal analysis of timing of expected future successful auctions, collateralization of underlying assets of the security and credit quality of the security. We re-evaluated the valuation of these securities as of December 31, 2013 and the temporary impairment amount decreased $68 from $260 at December 31, 2012 to $192. All income generated from these investments was recorded as interest income (see Note 4).
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	In-Process Research and Development and Goodwill
	The fair values of in-process research and development (IPR&D) acquired in business combinations are capitalized. The Company utilizes the "income method," which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each project independently. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. IPR&D intangible assets which are determined to have a decline in their fair value are adjusted downward and an expense is recognized as part of the general and administrative expenses in the Consolidated Statements of Operations. These are tested at least annually or when a triggering event occurs that could indicate a potential impairment.
	Goodwill represents excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized, but is subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment. The Company determines whether goodwill may be impaired by comparing the fair value of the reporting unit, calculated as the product of shares outstanding and the share price as of the end of a period, to its carrying value. No goodwill impairment has been recognized as of December 31, 2013. The Company has determined that it has only one reporting unit, which includes the acquired Molecular Insight.
	The following table reflects the components of the finite lived intangible assets as of December 31, 2013:
			Gross		Accumulated			Net Carrying
			Amount		Amortization			Value
	Finite lived intangible assets		$	21	$	2		$	19
	Total		$	21	$	2		$	19
	The weighted-average remaining life of the finite lived intangible assets is five years at December 31, 2013.
	Amortization expense is calculated on a straight-line basis over the estimated useful life of the asset. Amortization expense for the period from January 18, 2013 to December 31, 2013 was $2. Estimated amortization expense related to intangible assets existing as of December 31, 2013 is approximately $4 annually for each of the succeeding five years.
	The following table summarizes the activity related to the Company's goodwill and indefinite lived IPR&D:
			Goodwill		IPR&D
	Balance at January 1, 2013		$	-	$	-
	Increase related to MIP acquisition			7,702		32,300
	Reclassification to finite lived IPR&D			-		(21	)
	Impairment			-		(919	)
	Balance at December 31, 2013		$	7,702	$	31,360
Fair Value Measurements	'
	Fair Value Measurements
	In accordance with ASC 820 Fair Value Measurements and Disclosures, we use a three-level hierarchy for fair value measurements of certain assets and liabilities for financial reporting purposes that distinguishes between market participant assumptions developed from market data obtained from outside sources (observable inputs) and our own assumptions about market participant assumptions developed from the best information available to us in the circumstances (unobservable inputs). We assign hierarchy levels to assets constituting our available-for-sale portfolio and to our contingent consideration liability arising from the MIP acquisition based on our assessment of the transparency and reliability of the inputs used in the valuation. ASC 820 defines the three hierarchy levels as:
	·	Level 1 - Valuations based on unadjusted quoted market prices in active markets for identical securities.
	·	Level 2 - Valuations based on observable inputs other than Level 1 prices, such as quoted prices for similar assets at the measurement date, quoted prices in markets that are not active or other inputs that are observable, either directly or indirectly.
	·	Level 3 - Valuations based on unobservable inputs that are significant to the overall fair value measurement, which as noted above involve management judgment.
	Recurring Fair Value Measurements
	We believe the carrying amounts of the Company's cash equivalents, accounts receivable, other current assets, other assets (restricted cash providing collateral for a letter of credit securing lease obligations) and accounts payable and accrued expenses approximated their fair values as of December 31, 2013 and 2012, due to their short-term nature; we consider them Level 1 instruments.
	The fair value of the contingent consideration liability, consisting of future potential milestone payments related to the MIP acquisition was $15.7 million as of December 31, 2013 and $15.9 million as January 18, 2013, the acquisition date (see Note 2). The fair value of the contingent consideration liability is categorized as a Level 3 instrument, as displayed in Note 4. The Company records the contingent consideration liability at fair value with changes in estimated fair values recorded in general and administrative expenses in the Consolidated Statements of Operations. As of December 31, 2013, we reassessed the fair value of the contingent consideration and recorded a $0.2 million decrease, due to an increase in the discount period, and a corresponding credit in the general and administrative expenses in the fourth quarter of 2013. The December 31, 2013 contingent consideration of $15.7 million results from probability adjusted discounted cash flow and Monte Carlo simulation models which include estimates of significant milestone payments to former MIP stockholders under the acquisition agreement ranging from 2017 to 2022 and risk adjusted discount rates ranging from 10% to 12.5%.
	Nonrecurring Fair Value Measurements
	The Company's non-financial assets, such as intangible assets and property and equipment, are measured and recorded at fair value on the acquisition date, and if indicators of impairment exist, we assess recoverability by measuring the amount of any impairment by comparing the carrying value of the asset to its then-current estimated fair value (for intangible assets) or to market prices for similar assets (for property and equipment). If the carrying value is not recoverable we record an impairment charge as a general and administrative expense in the Consolidated Statements of Operations. The company reassessed the value of the indefinite lived intangible assets and recorded a non-cash charge to earnings of $919 in the fourth quarter of 2013. This impairment was the result of change in the Level 3 assumptions: (i) the timing of the estimated beginning of cash inflows from 2014 to 2018 and (ii) an increase in discount rate from 15% to 18% for the Onalta intangible asset. In connection with the second quarter amendment of the Company's Tarrytown lease, we recognized impairment losses of $347 on leasehold improvements and machinery and equipment removed from service which are included in Research and development expenses in our accompanying Consolidated Statements of Operations for the year ended December 31, 2013. As a result of closing our biologics pilot facilities in 2011, an impairment loss of $22 was included in Research and development expenses in our accompanying Consolidated Statement of Operations during 2011. No impairments occurred for the year ended December 31, 2012.
	Other current assets are comprised of prepaid expenses, interest, deferred tax asset and other receivables of $1,943 and $1,692 at December 31, 2013 and 2012, respectively, which are expected to be settled within one year. Restricted cash of $157 and $150 at December 31, 2013 and 2012, respectively, consists of collateral for a letter of credit securing lease obligations. We believe the carrying value of these assets approximates fair value.
Fixed Assets	'
	Fixed Assets
	Leasehold improvements, furniture and fixtures, and equipment are stated at cost. Furniture, fixtures and equipment are depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized on a straight-line basis over the life of the lease or of the improvement, whichever is shorter. Costs of construction of long-lived assets are capitalized but are not depreciated until the assets are placed in service.
	Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred. The cost and accumulated depreciation of assets retired or sold are removed from the respective accounts and any gain or loss is recognized in operations. The estimated useful lives of fixed assets are as follows:
	Computer equipment	3 years
	Machinery and equipment	5-7 years
	Furniture and fixtures	5 years
	Leasehold improvements	Earlier of life of improvement or lease
Deferred Lease Liability and Incentive	'
	Deferred Lease Liability and Incentive
	Our lease agreements include fixed escalations of minimum annual lease payments and we recognize rental expense on a straight-line basis over the lease terms and record the difference between rent expense and current rental payments as deferred rent. Deferred lease incentive includes a construction allowance from our landlord which is amortized as a reduction to rental expense on a straight-line basis over the lease term. As of December 31, 2013 and 2012, the Consolidated Balance Sheets include the following:
			2013		2012
	Other current liabilities:
	Deferred lease incentive		$	115	$	115
	Total other current liabilities		$	115	$	115
	Other liabilities:
	Deferred lease liability		$	224	$	273
	Deferred lease incentive			690		805
	Total other liabilities		$	914	$	1,078
Income Taxes	'
	Income Taxes
	We account for income taxes in accordance with the provisions of ASC 740 Income Taxes, which requires that we recognize deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (temporary differences) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. A valuation allowance is established for deferred tax assets for which realization is uncertain.
	In accordance with ASC 718 Compensation – Stock Compensation and ASC 505 Equity, we have made a policy decision related to intra-period tax allocation, to account for utilization of windfall tax benefits based on provisions in the tax law that identify the sequence in which amounts of tax benefits are used for tax purposes (i.e., tax law ordering).
	Uncertain tax positions are accounted for in accordance with ASC 740 Income Taxes, which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that we have taken or expect to take on a tax return. ASC 740 applies to income taxes and is not intended to be applied by analogy to other taxes, such as sales taxes, value-add taxes, or property taxes. We review our nexus in various tax jurisdictions and our tax positions related to all open tax years for events that could change the status of our ASC 740 liability, if any, or require an additional liability to be recorded. Such events may be the resolution of issues raised by a taxing authority, expiration of the statute of limitations for a prior open tax year or new transactions for which a tax position may be deemed to be uncertain. Those positions, for which management's assessment is that there is more than a 50 percent probability of sustaining the position upon challenge by a taxing authority based upon its technical merits, are subjected to the measurement criteria of ASC 740. We record the largest amount of tax benefit that is greater than 50 percent likely of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. Any ASC 740 liabilities for which we expect to make cash payments within the next twelve months are classified as "short term." In the event that we conclude that we are subject to interest and/or penalties arising from uncertain tax positions, we will record interest and penalties as a component of income taxes (see Note 13).
Risks and Uncertainties	'
	Risks and Uncertainties
	We have to date relied principally on external funding, collaborations with Salix, Fuji and others, out-licensing and asset sale arrangements, royalty and product revenue to finance our operations. There can be no assurance that our research and development will be successfully completed, that any products developed will obtain necessary marketing approval by regulatory authorities or that any approved products will be commercially viable. In addition, we operate in an environment of rapid change in technology, and we are dependent upon satisfactory relationships with our partners and the continued services of our current employees, consultants and subcontractors. We are also dependent upon Salix, Fuji and Ono fulfilling their manufacturing obligations, either on their own or through third-party suppliers. For 2013, 2012 and 2011, the primary sources of our revenues were Salix, Ono, Fuji, asset out-licensing and disposition, and research grant revenues from the NIH. There can be no assurance that revenues from asset out-licensing and disposition, Salix, Ono and Fuji or from research awards will continue. Substantially all of our accounts receivable at December 31, 2013 and 2012 were from the above-named sources.
Comprehensive (Loss) Income	'
	Comprehensive (Loss) Income
	Comprehensive (loss) income represents the change in net assets of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive (loss) income includes net (loss) income adjusted for the change in net unrealized gain or loss on auction rate securities. The disclosures required by ASC 220 Comprehensive Income for 2013, 2012 and 2011 have been included in the Consolidated Statements of Comprehensive (Loss) Income. There was no income tax expense/benefit allocated to any component of Other Comprehensive (Loss) Income (see Note 13).
Impact of Recently Adopted Accounting Standards	'
	Impact of Recently Adopted Accounting Standards
	In February 2013, the FASB issued ASU No. 2013-02, which requires presentation of amounts reclassified out of accumulated other comprehensive income by component. The ASU is effective for reporting periods beginning after December 15, 2012. We adopted this new standard on January 1, 2013 and it had no material impact on our consolidated financial statements.

Acquisition_of_Molecular_Insig1

Acquisition of Molecular Insight Pharmaceuticals, Inc (Tables)	12 Months Ended
	Dec. 31, 2013
Acquisition of Molecular Insight Pharmaceuticals, Inc [Abstract]	'
Schedule Purchase Price Allocation [Table Text Block]	'
	Purchase Price Allocation: We have accounted for the Molecular Insight acquisition by allocating our estimate of the fair market value of the consideration we paid to the fair values of the assets acquired and liabilities assumed at the effective date of the acquisition, estimated using the valuation models summarized below. Given the uniqueness of and uncertainties attendant to the assets and liabilities, the derived values do not reflect actual transactions or quoted prices. Acquired intangible assets, including goodwill, are not deductible for tax purposes.
		Amount
	Consideration:
	Progenics common stock consideration paid	$	11,265
	Contingent consideration (pursuant to future milestone obligations)		15,900
	Total consideration		27,165
	Tangible assets acquired and liabilities assumed:
	Cash and cash equivalents		1,888
	Accounts receivable		56
	Other current assets		529
	Fixed assets		249
	Accounts payable, accrued expenses and deferred revenue - current		(2,876	)
	Deferred tax liability – long term		(12,683	)
	Total tangible assets acquired and liabilities assumed		(12,837	)
	Intangible assets – in process research and development		32,300
	Total tangible and intangible assets acquired and liabilities assumed		19,463
	Goodwill	$	7,702
Business Acquisition, Pro Forma Information	'
	Pro forma financial information (unaudited): The following unaudited pro forma information presents the results of operations of the combined companies for the periods indicated as if the acquisition had been consummated on January 1, 2012, combining the respective historical results of Progenics and MIP for each period. Non-recurring transaction expenses of $790, incurred in the year ended December 31, 2013, are reflected in the pro forma information as if these were incurred in the corresponding 2012 period, due to the pro forma assumption of January 1, 2012 as the date of the acquisition consummation.
		Three Months Ended						Year Ended
		December 31,						December 31,
		2013			2012			2013			2012
	Revenues	$	2,968		$	12,801		$	7,867		$	18,235
	Net loss		(8,551	)		(3,458	)		(43,736	)		(57,877	)
	Basic and diluted loss per share		(0.14	)		(0.08	)		(0.78	)		(1.48	)

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Components of finite lived intangible assets [Text Block]	'
	The following table reflects the components of the finite lived intangible assets as of December 31, 2013:
			Gross		Accumulated			Net Carrying
			Amount		Amortization			Value
	Finite lived intangible assets		$	21	$	2		$	19
	Total		$	21	$	2		$	19
	The weighted-average remaining life of the finite lived intangible assets is five years at December 31, 2013.
Activity related to goodwill and indefinite lived intangible assets [Text Block]	'
	The following table summarizes the activity related to the Company's goodwill and indefinite lived IPR&D:
			Goodwill		IPR&D
	Balance at January 1, 2013		$	-	$	-
	Increase related to MIP acquisition			7,702		32,300
	Reclassification to finite lived IPR&D			-		(21	)
	Impairment			-		(919	)
	Balance at December 31, 2013		$	7,702	$	31,360
Schedule of estimated useful lives of fixed assets	'
	Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred. The cost and accumulated depreciation of assets retired or sold are removed from the respective accounts and any gain or loss is recognized in operations. The estimated useful lives of fixed assets are as follows:
	Computer equipment	3 years
	Machinery and equipment	5-7 years
	Furniture and fixtures	5 years
	Leasehold improvements	Earlier of life of improvement or lease
Deferred leases	'
	Deferred Lease Liability and Incentive
	Our lease agreements include fixed escalations of minimum annual lease payments and we recognize rental expense on a straight-line basis over the lease terms and record the difference between rent expense and current rental payments as deferred rent. Deferred lease incentive includes a construction allowance from our landlord which is amortized as a reduction to rental expense on a straight-line basis over the lease term. As of December 31, 2013 and 2012, the Consolidated Balance Sheets include the following:
			2013		2012
	Other current liabilities:
	Deferred lease incentive		$	115	$	115
	Total other current liabilities		$	115	$	115
	Other liabilities:
	Deferred lease liability		$	224	$	273
	Deferred lease incentive			690		805
	Total other liabilities		$	914	$	1,078

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements [Abstract]	'
Assets measured at fair value on recurring basis	'
	The following tables present our money market funds, included in cash and cash equivalents, and auction rate securities assets and contingent consideration liability measured at fair value on a recurring basis as of the dates indicated, classified by valuation hierarchy:
					Fair Value Measurements at December 31, 2013
		Balance at			Quoted Prices in Active Markets for Identical Assets			Significant Other Observable Inputs		Significant Unobservable Inputs
		31-Dec-13			(Level 1)			(Level 2)		(Level 3)
	Assets:
	Money market funds	$	60,364		$	60,364		$	-	$	-
	Auction rate securities		2,208			-			-		2,208
	Total Assets	$	62,572		$	60,364		$	-	$	2,208
	Liability:
	Contingent consideration	$	15,700		$	-		$	-	$	15,700
	Total Liability	$	15,700		$	-		$	-	$	15,700
					Fair Value Measurements at December 31, 2012
		Balance at			Quoted Prices in Active Markets for Identical Assets			Significant Other Observable Inputs		Significant Unobservable Inputs
		31-Dec-12			(Level 1)			(Level 2)		(Level 3)
	Money market funds	$	56,224		$	56,224		$	-	$	-
	Auction rate securities		3,240			-			-		3,240
	Total	$	59,464		$	56,224		$	-	$	3,240
Summary of activities in financial instruments with Level 3 inputs	'
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activities for the periods indicated:
		Asset – Auction Rate Securities
		Fair Value Measurements Using Significant
		Unobservable Inputs
		(Level 3)
	Description	2013			2012
	Balance at beginning of period	$	3,240		$	3,332
	Transfers into Level 3		-			-
	Total realized/unrealized gains (losses)
	Included in net income (loss)		-			-
	Included in comprehensive income (loss)		68			8
	Settlements		(1,100	)		(100	)
	Balance at end of period	$	2,208		$	3,240
	Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date	$	-		$	-
		Liability – Contingent Consideration
		Fair Value Measurements Using Significant
		Unobservable Inputs
		(Level 3)
	Description	2013			2012
	Balance at beginning of period	$	-		$	-
	Fair value of contingent consideration – acquisition of Molecular Insight		15,900			-
	Fair value adjustment to contingent consideration included in net loss		(200	)		-
	Balance at end of period	$	15,700		$	-
	Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$	(200	)	$	-
Schedule of amortized cost basis, the aggregate fair value and gross unrealized holdings	'
	The following tables summarize the amortized cost basis, the aggregate fair value and gross unrealized holding gains and losses at December 31, 2013 and 2012:
		Amortized			Fair			Unrealized Holding
	2013:00:00	Cost Basis			Value			Gains		(Losses)			Net
	Maturities greater than ten years:
	Auction rate securities	$	2,400		$	2,208		$	-	$	(192	)	$	(192	)
		$	2,400		$	2,208		$	-	$	(192	)	$	(192	)
		Amortized			Fair			Unrealized Holding
	2012:00:00	Cost Basis			Value			Gains		(Losses)			Net
	Maturities greater than ten years:
	Auction rate securities	$	2,500		$	2,300		$	-	$	(200	)	$	(200	)
	Investments without stated maturity dates:
	Auction rate securities		1,000			940			-		(60	)		(60	)
		$	3,500		$	3,240		$	-	$	(260	)	$	(260	)
Schedule of gross unrealized losses and fair value of our marketable securities	'
	The following table shows the gross unrealized losses and fair value of our auction rate securities with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position, at December 31, 2013 and 2012.
	2013:00:00	Less than 12 Months						12 Months or Greater					Total
	Description of Securities	Fair Value			Unrealized Losses			Fair Value		Unrealized Losses			Fair Value			Unrealized Losses
	Auction rate securities	$	-		$	-		$	2,208	$	(192	)	$	2,208		$	(192	)
	Total	$	-		$	-		$	2,208	$	(192	)	$	2,208		$	(192	)
	2012:00:00	Less than 12 Months						12 Months or Greater					Total
	Description of Securities	Fair Value			Unrealized Losses			Fair Value		Unrealized Losses			Fair Value			Unrealized Losses
	Auction rate securities	$	-		$	-		$	3,240	$	(260	)	$	3,240		$	(260	)
	Total	$	-		$	-		$	3,240	$	(260	)	$	3,240		$	(260	)

Accounts_Receivable_Tables

Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2013
Accounts Receivable [Abstract]	'
Accounts Receivable	'
	Our accounts receivable represent amounts due to Progenics from collaborators, royalties, research grants and the sales of research reagents and as of December 31, 2013 and 2012, consisted of the following:
		2013			2012
	Collaborators	$	12		$	6,125
	Royalties		2,862			781
	Research grants		-			12
	Other		12			19
			2,886			6,937
	Less, allowance for doubtful accounts		(7	)		-
	Total	$	2,879		$	6,937

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Fixed Assets [Abstract]	'
Fixed Assets	'
	6. Fixed Assets
	Fixed assets as of December 31, 2013 and 2012 consisted of the following:
		2013			2012
	Computer equipment	$	2,234		$	2,166
	Machinery and equipment		7,091			8,031
	Furniture and fixtures		170			133
	Leasehold improvements		5,020			5,327
	Other		16			12
			14,531			15,669
	Less, accumulated depreciation and amortization		(12,118	)		(12,270	)
	Total	$	2,413		$	3,399
	At December 31, 2013 and 2012, $2.0 million and $2.6 million, respectively, of leasehold improvements, net were being amortized over periods of 8.5-10.8 years, under leases with terms through December 31, 2020.

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Accounts Payable and Accrued Expenses [Abstract]	'
Schedule of accounts payable and accrued expenses	'
	The carrying value of our accounts payable and accrued expenses approximates fair value, as it represents amounts due to vendors and employees, which will be satisfied within one year. Accounts payable and accrued expenses as of December 31, 2013 and 2012, consisted of the following:
		2013		2012
	Accrued consulting and clinical trial costs	$	2,672	$	2,193
	Accrued payroll and related costs		2,123		1,552
	Restructuring accrual		-		813
	Legal and professional fees		608		774
	Accounts payable		793		229
	Other		316		79
	Total	$	6,512	$	5,640

Restructuring_Tables

Restructuring (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring [Abstract]	'
Activity in restructuring accrual	'
	Activity in the restructuring accrual, which is included in accounts payable and accrued expenses in our Consolidated Balance Sheets, and in research and development and general and administrative expenses in the Consolidated Statements of Operations, is specified below.
		Severance and Related Benefits			Other Exit Costs			Contract Termination Costs			Total Restructuring Accrual
	Balance at December 31, 2010	$	-		$	-		$	-		$	-
	Additions, net		1,341			8			292			1,641
	Payments		(770	)		(2	)		(138	)		(910	)
	Balance at December 31, 2011		571			6			154			731
	Additions, net		1,905			184			3			2,092
	Payments		(1,663	)		(190	)		(157	)		(2,010	)
	Balance at December 31, 2012		813			-			-			813
	Additions, net		1,492			15			1,359			2,866
	Payments		(2,305	)		(15	)		(1,359	)		(3,679	)
	Balance at December 31, 2013	$	-		$	-		$	-		$	-

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Schedule of future minimum annual payments	'
	As of December 31, 2013, future minimum annual payments under all operating lease agreements are as follows:
	Years ending December 31,	Minimum
		Annual Payments
	2014	$	1,841
	2015		1,887
	2016		1,934
	2017		1,983
	2018		2,032
	Thereafter		4,218
	Total	$	13,895
Schedule of licensing, service and supply agreements	'
	b. Licensing, Service and Supply Agreements
	Progenics and its subsidiaries have entered into intellectual property-based license and service agreements in connection with product development programs, and have recognized milestone, license and sublicense fees and supply costs, included in research and development expenses, totaling approximately $567, $1,170 and $578 during the last three years, respectively.
		Paid from inception to December 31, 2013		Future (1)		Terms
				Commitments
	Progenics agreements with:
	Lonza Sales AG	$	909	$	824	Annual license fee payments, milestones and royalties, as applicable, in respect of oncology and other products.
	PSMA LLC agreements with:
	Seattle Genetics, Inc.		4,400		13,900	Milestone and periodic maintenance payments to use ADC technology to link chemotherapeutic agents to monoclonal antibodies that target prostate specific membrane antigen. ADC technology is based in part on technology licensed by SGI from third parties.
	Amgen Fremont, Inc. (formerly Abgenix)		1,350		5,750	Milestones and royalties to use XenoMouse® technology for generating fully human antibodies to PSMA LLC's PSMA antigen.
	Former member of PSMA LLC		278		52,188	Annual minimum royalty payments and milestones to use technology related to PSMA.
		Paid from acquisition date to December 31, 2013		Future (1)		Terms
				Commitments
	MIP agreements with:
	University of Zurich and the Paul Scherrer Institute		65		1,225	Annual maintenance and license fee payments, milestones and royalties in respect of licensed technology related to 1404.
	University of Western Ontario		4		374	Annual minimum royalty, administration and milestone payments in respect of licensed technology related to Azedra.
	Novartis Pharma AG and other interests		-		4,600	Milestone and royalty payments in respect of licensed technology related to Onalta.
	Bayer Schering Pharma AG		-		9,000	Milestone and royalty payments in respect of licensed technology related to a MIP asset.
	(1) Amounts based on known contractual obligations as specified in the respective license agreements, which are dependent on the achievement or occurrence of future milestones or events and exclude amounts for royalties which are dependent on future sales and are unknown.
	We are seeking to out-license or terminate non-germane Molecular Insight licenses and service agreements, as to which we have paid $216 through December 31, 2013, and have future commitments of $3,453, subject to occurrence of future milestones or events.

ShareBased_Payment_Arrangement1

Share-Based Payment Arrangements (Tables)	12 Months Ended
	Dec. 31, 2013
Share-Based Payment Arrangements [Abstract]	'
Assumptions used in computing the fair value of option grants	'
	Under ASC 718 Compensation – Stock Compensation, the fair value of each non-qualified stock option award is estimated on the date of grant using the Black-Scholes option pricing model, which requires input assumptions noted in the following table. Ranges of assumptions for inputs are disclosed where the value of such assumptions varied during the related period. Historical volatilities are based upon daily quoted market prices of our common stock on The NASDAQ Stock Market LLC over a period equal to the expected term of the related equity instruments. We rely only on historical volatility since it provides the most reliable indication of future volatility. Future volatility is expected to be consistent with historical; historical volatility is calculated using a simple average calculation; historical data is available for the length of the option's expected term and a sufficient number of price observations are used consistently. Since our stock options are not traded on a public market, we do not use implied volatility. For 2013, 2012 and 2011 our expected term was calculated based upon historical data related to exercise and post-termination cancellation activity; accordingly, for grants issued to employees and directors and officers (excluding our former CEO in 2011), we are using expected terms of 5.3 and 7.4 years, 5.4 and 7.4 years and 5.3 and 7.4 years, respectively. The expected term of stock options granted to our former CEO in 2011 was calculated separately from stock options granted to employees and directors and officers, and was 8 years for 2011. The expected term for options granted to non-employees was also calculated separately from stock options granted to employees and directors and officers and was ten years, which is the contractual term of those options. We have never paid dividends and do not expect to pay dividends in the future. Therefore, our dividend rate is zero. The risk-free rate for periods within the expected term of the options is based on the U.S. Treasury yield curve in effect at the time of grant. The following table presents assumptions used in computing the fair value of option grants during 2013, 2012 and 2011:
		2013			2012			2011
	Expected volatility		73% – 90	%		70% – 85	%		68% – 78	%
	Expected dividends	Zero			Zero			Zero
	Expected term (years)		5.3 – 10			5.3 – 10			5.3 – 10
	Weighted average expected term (years)		5.96			6.11			6.17
	Risk-free rate		0.76% – 2.83	%		0.57% – 1.71	%		0.77% – 2.97	%
Summary of option activity under the Plans	'
	A summary of option activity under the Plans as of December 31, 2013 and changes during the year then ended is presented below:
	Options	Shares			Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Yr.)			Aggregate Intrinsic Value
	Outstanding at January 1, 2013		5,366		$	12.27
	Granted		1,018			5.13
	Exercised		(14	)		5.08
	Forfeited		(608	)		10.63
	Expired		(463	)		14.7
	Outstanding at December 31, 2013		5,299			10.89			5.82		$	304
	Exercisable at December 31, 2013		3,875		$	12.45			4.86		$	118
Status of outstanding restricted stock awarded	'
	A summary of the status of our outstanding restricted stock awarded under the Plans as of December 31, 2013 and changes during the year then ended is presented below:
	Restricted Stock Awards	Shares			Weighted Average Grant-Date
					Fair Value
	Nonvested at January 1, 2013		28		$	5.35
	Granted		-			-
	Vested		(27	)		5.35
	Forfeited		(1	)		5.35
	Nonvested at December 31, 2013		-		$	-
Assumption used for shares purchased under Purchase Plans	'
	The fair value of shares purchased under the Purchase Plans was estimated on the date of grant in accordance with ASC 718 Compensation – Stock Compensation, via the same option valuation model used for options granted under the Plans, but with the following assumptions during 2011:
		2011
	Expected volatility		43% – 51	%
	Expected dividends	zero
	Expected term	6 months
	Risk-free rate		0.06% – 0.22	%
Purchases of common stock under the Purchase Plans	'
	Purchases of common stock under the Purchase Plans during 2011 are summarized as follows:
		Qualified Plan									Non-Qualified Plan
		Shares Purchased			Price Range			Weighted			Shares Purchased		Price Range		Weighted
								Average Grant-Date Fair Value							Average Grant-Date Fair Value
	2011		428		$	4.62 – $5.65		$	0.88			162	$	4.62 – $5.65	$	0.84
Compensation expense of shares, granted to both employees and non-employees	'
	The total compensation expense of shares, granted to both employees and non-employees, under all of our share-based payment arrangements that was recognized in operations during 2013, 2012 and 2011 was:
		2013			2012			2011
	Recognized as:
	Research and Development	$	2,524		$	4,568		$	4,499
	General and Administrative		1,022			1,968			1,863
	Total	$	3,546		$	6,536		$	6,362

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Schedule of deferred tax assets and liabilities	'
	Deferred tax assets and liabilities as of December 31, 2013 and 2012, consisted of the following:
		2013			2012
	Deferred tax assets:
	Depreciation and amortization	$	6,165		$	6,497
	R&E tax credit carry-forwards		5,129			11,843
	NYS investment tax credit carry-forwards		1,095			1,084
	AMT credit carry-forwards		211			211
	Net operating loss carry-forwards		190,263			112,966
	Capitalized research and development expenditures		25,231			30,884
	Stock compensation		13,826			14,436
	Other items		1,097			2,193
	Total gross deferred tax assets		243,017			180,114
	Less: Valuation allowance		(243,017	)		(178,045	)
	Deferred tax assets		-			2,069
	Deferred tax liability - current		-			(2,069	)
	Deferred tax liability – long term		(12,321	)		-
	Net deferred tax liability	$	(12,321	)	$	-
Schedule of reconciliation of income taxes	'
	The following is a reconciliation of income taxes computed at the Federal statutory income tax rate to the actual effective income tax provision during 2013, 2012 and 2011:
		2013			2012			2011
	U.S. Federal statutory rate		(34.0	)%		(35.0	)%		35	%
	State income taxes, net of Federal benefit		(4.9	)		(5.4	)		8
	Research and experimental tax credit		(3.6	)		-			(4.1	)
	Change in valuation allowance		11.4			34.7			(22.6	)
	Effect of federal tax rate bracket change on valuation allowance		8.7			-			(34.8	)
	Equity compensation		3.1			4.2			17
	Investment tax credit		(0.1	)		-			(0.1	)
	NOL expiration – Section 382		18.6			-			-
	Other		-			1.5			1.6
	Income tax provision (benefit)		(0.8	)%		0	%		0	%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	'
	As of December 31, 2013, we have not recognized any liability for uncertain tax positions, because of our full valuation allowance. We will recognize interest and penalties related to these positions, should such costs be assessed. As of December 31, 2013, we have not recognized interest and penalties. The recognition of unrecognized tax benefits would not affect our effective tax rate because the tax benefit would be offset by an increase in our valuation allowance.
	The following is a tabular reconciliation of the total amounts of unrecognized tax benefits for the year ended December 31, 2013.
		2013
	Beginning uncertain tax benefits	$	2,661
	Current year - increases		-
	Current year - decreases		-
	Settlements		-
	Expired statuses		-
	Ending uncertain tax benefits	$	2,661

Net_Income_Loss_Per_Share_Tabl

Net Income (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Net Income (Loss) Per Share [Abstract]	'
Calculation of net loss per share, basic and diluted	'
	Our basic net (loss) income per share amounts have been computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the period. For 2013 and 2012, we reported net losses and, therefore, potential common shares were not included since such inclusion would have been anti-dilutive. For 2011, we reported net income, and the computation of diluted earnings per share is based upon the weighted-average number of our common shares and dilutive effect, determined using the treasury stock method, of potential common shares outstanding. As of December 31, 2012 and 2011, our 28 and 98, respectively, shares of unvested restricted stock with non-forfeitable rights to dividends were outstanding; all such shares were vested at the end of December 31, 2013. The allocation of 2012 net losses and the 2011 net income to these participating securities pursuant to the two-class method is not material to both basic and diluted earnings per share. The calculations of net loss per share, basic and diluted, are as follows:
		Net (Loss) Income			Weighted Average		Per Share
		(Numerator)			Common Shares		Amount
					(Denominator)
	2013:00:00
	Basic and diluted	$	(42,572	)		55,798	$	(0.76	)
	2012:00:00
	Basic and diluted	$	(35,431	)		34,754	$	(1.02	)
	2011:00:00
	Basic	$	10,381			33,375	$	0.31
	Dilutive effect of stock options		-			66
	Dilutive effect of restricted stock		-			53
	Diluted	$	10,381			33,494	$	0.31
Schedule of antidilutive common shares excluded from computation of diluted earnings per share	'
	During 2013, 2012 and 2011, anti-dilutive common shares excluded from diluted per share amounts consist of the following:
		2013					2012					2011
		Weighted			Weighted		Weighted			Weighted		Weighted		Weighted
		Average			Average		Average			Average		Average		Average
		Number			Exercise Price		Number			Exercise Price		Number		Exercise Price
	Options		5,969		$	11.54		5,947		$	12.32		4,543	$	14.92
	Restricted stock		-					60					45
	Total		5,969					6,007					4,588

Unaudited_Quarterly_Results_un1

Unaudited Quarterly Results (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Unaudited Quarterly Results (unaudited) [Abstract]	'
Summarized quarterly financial data	'
	Summarized quarterly financial data during 2013 and 2012 are as follows:
			2013 Quarter Ended
			31-Mar			30-Jun			30-Sep			31-Dec
	Revenues		$	2,226		$	1,801		$	867		$	2,968
	Net loss			(11,258	)		(12,263	)		(10,500	)		(8,551	)
	Net loss per share - basic and diluted			(0.22	)		(0.24	)		(0.17	)		(0.14	)
			2012 Quarter Ended
			31-Mar			30-Jun			30-Sep			31-Dec
	Revenues (1)		$	2,226		$	1,820		$	1,117		$	8,885
	Net loss			(13,086	)		(10,720	)		(11,301	)		(324	)
	Net loss per share - basic and diluted			(0.39	)		(0.32	)		(0.33	)		(0.01	)
	_______________
	-1	Revenues in the fourth quarter of 2012 include $5.0 million and $2.8 million from the MedImmune and CytoDyn Agreements, respectively.

Organization_and_Business_Deta

Organization and Business (Details) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Organization and Business [Abstract]	'	'	'	'	'	'
Common stock, issued (in shares)	9,775	8,750	9,800	'	'	'
Common stock public offering price (in dollars per share)	'	$4.60	$4.40	'	'	'
Common stock public offering proceeds	$40,100,000	$37,500,000	$40,078,000	$23,348,000	$0	'
Funding and Financial Matters [Abstract]	'	'	'	'	'	'
Cash and cash equivalents at end of period	'	'	65,860,000	58,838,000	70,105,000	47,918,000
Decrease in cash and cash equivalents	'	'	7,022,000	-11,267,000	22,187,000	'
Minimum number of years cash will fund operations	'	'	'1 year	'	'	'
Cash, cash equivalents and auction rate securities	'	'	68,068,000	62,078,000	'	'
Increase in cash, cash equivalents and auction rate securities	'	'	$6,000,000	'	'	'

Acquisition_of_Molecular_Insig2

Acquisition of Molecular Insight Pharmaceuticals, Inc (Details) (USD $)	1 Months Ended	3 Months Ended			12 Months Ended
	Jan. 18, 2013	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]	'	'	'	'	'	'	'
Original Shares Issued For Acquisition	4,566,210	'	'	'	'	'	'
Shares For Acquisition Held In Escrow	500,000	'	'	'	'	'	'
Shares For Acquisition Returned From Escrow	93,847	'	'	'	'	'	'
Maximum Milestone Payment Specified Commercial Events	'	$23,000,000	'	'	$23,000,000	'	'
Maximum Milestone Payment For Achieving Sales Targets	'	70,000,000	'	'	70,000,000	'	'
Closing price of Progenics' common shares	$2.83	'	'	'	'	'	'
Business Acquisition, Cost of Acquired Entity, Transaction Costs	'	'	'	'	790,000	'	'
Business Acquisition Contributed Revenue	'	'	'	'	884,000	'	'
Business Acquisition Contributed Net Loss	'	'	'	'	11,379,000	'	'
Equity issuance costs in connection with acquisition of subsidiary	'	'	45,000	'	45,000	0	0
Progenics common stock consideration	11,265,000	'	'	'	'	'	'
Acquisition-related contingent consideration liability	15,900,000	15,700,000	'	0	15,700,000	0	0
Business Entity Acquisition, Cost of Acquired Entity, Purchase Price	27,165,000	11,265,000	'	0	11,265,000	0	0
Cash acquired in acquisition of subsidiary	1,888,000	'	'	'	'	'	'
Business Acquisition, Purchase Price Allocation, Current Assets, Receivables	56,000	'	'	'	'	'	'
Business Acquisition, Purchase Price Allocation, Current Assets, Prepaid Expense and Other Assets	529,000	'	'	'	'	'	'
Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment	249,000	'	'	'	'	'	'
Business Acquisition, Purchase Price Allocation, Current Liabilities	-2,876,000	'	'	'	'	'	'
Deferred tax liability - long term	-12,683,000	-12,321,000	'	0	-12,321,000	0	'
Business Entity Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net	-12,837,000	'	'	'	'	'	'
Intangible assets	32,300,000	'	'	'	'	'	'
Business Acquisition Tangible And Intangible Assets Acquired Liabilities Assumed	19,463,000	'	'	'	'	'	'
Goodwill	7,702,000	'	'	'	'	'	'
Business Acquisition Transaction Costs Excluded From Pro Forma Information	'	'	'	'	790,000	'	'
Business Acquisition, Pro Forma Revenue	'	2,968,000	'	12,801,000	7,867,000	18,235,000	'
Business Acquisition, Pro Forma Net Income (Loss)	'	-8,551,000	'	-3,458,000	-43,736,000	-57,877,000	'
Business Acquisition Pro Forma Earnings Per Share Basic And Diluted	'	($0.14)	'	($0.08)	($0.78)	($1.48)	'
Azedra [Member]	'	'	'	'	'	'	'
Fair Value Measurements [Abstract]	'	'	'	'	'	'	'
Discount rate	15.00%	'	'	'	'	'	'
Beginning of significant cash inflows - year	'2017	'	'	'	'	'	'
Fair Value	4,900,000	'	'	'	'	'	'
MIP 1404 [Member]	'	'	'	'	'	'	'
Fair Value Measurements [Abstract]	'	'	'	'	'	'	'
Discount rate	18.00%	'	'	'	'	'	'
Beginning of significant cash inflows - year	'2017	'	'	'	'	'	'
Fair Value	23,200,000	'	'	'	'	'	'
Onalta [Member]	'	'	'	'	'	'	'
Fair Value Measurements [Abstract]	'	'	'	'	'	'	'
Discount rate	15.00%	'	'	'	'	'	'
Beginning of significant cash inflows - year	'2014	'	'	'	'	'	'
Fair Value	1,500,000	'	'	'	'	'	'
Small Molecule [Member]	'	'	'	'	'	'	'
Fair Value Measurements [Abstract]	'	'	'	'	'	'	'
Discount rate	20.00%	'	'	'	'	'	'
Beginning of significant cash inflows - year	'2021	'	'	'	'	'	'
Fair Value	2,700,000	'	'	'	'	'	'
Contingent Consideration Liability [Member]	'	'	'	'	'	'	'
Fair Value Measurements [Abstract]	'	'	'	'	'	'	'
Fair Value	$15,900,000	'	'	'	'	'	'
Minimum [Member] | Contingent Consideration Liability [Member]	'	'	'	'	'	'	'
Fair Value Measurements [Abstract]	'	'	'	'	'	'	'
Discount rate	10.00%	'	'	'	'	'	'
Beginning of significant cash inflows - year	'2016	'	'	'	'	'	'
Maximum [Member] | Contingent Consideration Liability [Member]	'	'	'	'	'	'	'
Fair Value Measurements [Abstract]	'	'	'	'	'	'	'
Discount rate	12.50%	'	'	'	'	'	'
Beginning of significant cash inflows - year	'2022	'	'	'	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

Share data in Thousands, unless otherwise specified

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 18, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Jun. 30, 2011

Dec. 31, 2012

Jun. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2008

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Computer Equipment [Member]

Furniture and Fixtures [Member]

Leasehold Improvements [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Money Market Funds [Member]

Money Market Funds [Member]

Commercial Bank [Member]

Commercial Bank [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Salix Agreement [Member]

Salix Agreement [Member]

Salix Agreement [Member]

Salix Agreement [Member]

Salix Agreement [Member]

Salix Agreement [Member]

Salix Agreement [Member]

Salix Agreement [Member]

Ono Agreement [Member]

Ono Agreement [Member]

MedImmune Agreement [Member]

CytoDyn Agreement [Member]

Onalta Agreement [Member]

Machinery and Equipment [Member]

Leasehold Improvements [Member]

Leasehold Improvements [Member]

Machinery and Equipment [Member]

Leasehold Improvements [Member]

Leasehold Improvements [Member]

License [Member]

License [Member]

Reimbursable Development Services [Member]

Reimbursable Development Services [Member]

Reimbursable Development Services [Member]

Reimbursable Development Services [Member]

Participation in Joint Committees [Member]

Revenue Recognition [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront license fee, received

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$60,000,000

'

$58,400,000

'

'

$1,100,000

'

$500,000

$15,000,000

'

'

$3,500,000

$200,000

Upfront license fee, receivable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

Deferred Revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

Additional license fees receivable upon achievement of development milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

Collaboration Revenue

'

'

1,595,000

8,525,000

76,764,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

58,400,000

'

1,100,000

200,000

200,000

59,600,000

'

'

'

'

'

'

Shares of unvested restricted stock outstanding (in shares) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of unvested restricted stock outstanding (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

28

98

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and Cash Equivalents [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash equivalents

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,364,000

56,224,000

4,898,000

2,614,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts Receivable [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allowance for Doubtful Accounts Receivable, Current

7,000

'

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Auction Rate Securities [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Auction rate securities

2,208,000

'

2,208,000

3,240,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Decrease in temporary impairment of auction rate securities

'

'

68,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of temporary impairment

'

'

192,000

260,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill and indefinite lived in-process research and development [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

7,702,000

'

7,702,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Acquired During Period

'

'

7,702,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible Assets Acquired During Period

'

'

32,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indefinite-Lived Intangible Assets (Excluding Goodwill)

31,360,000

'

31,360,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification to finite lived in-process research and development

'

'

-21,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of Intangible Assets (Excluding Goodwill)

'

'

-919,000

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Gross

21,000

'

21,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Accumulated Amortization

2,000

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Net, Total

19,000

'

19,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Asset, Useful Life

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated amortization of intangible assets for succeeding five years

'

'

4,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Measurements [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration liability

15,700,000

'

15,700,000

0

0

15,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of milestone achievement - Minimum

'2017

'

'2017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of milestone achievement - Maximum

'2022

'

'2022

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Inputs, Discount Rate - Minimum

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Inputs, Discount Rate - Maximum

'

'

12.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum year of beginning cash inflows

'

'

'

'

'

'2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum year of beginning cash inflows

'2018

'

'2018

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount Rate - Minimum

'

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount Rate - Maximum

18.00%

'

18.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

200,000

'

-200,000

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible impairment charge

'

'

919,000

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other current assets

1,943,000

'

1,943,000

1,692,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted cash

157,000

'

157,000

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other Asset Impairment Charges

'

347,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful lives of fixed assets [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated useful life

'

'

'

'

'

'

'3 years

'5 years

'

'5 years

'8 years 6 months

'8 years 6 months

'7 years

'10 years 9 months 18 days

'10 years 9 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful life description

'

'

'

'

'

'

'

'

'Earlier of life of improvement or lease

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Lease Liability and Incentive [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred lease incentive

115,000

'

115,000

115,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total other current liabilities

115,000

'

115,000

115,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred lease liability

224,000

'

224,000

273,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred lease incentive

690,000

'

690,000

805,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total other liabilities

914,000

'

914,000

1,078,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of Long-Lived Assets [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment loss

'

'

'

'

$22,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income Taxes [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of income tax benefit realization (in hundredths)

50.00%

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Jan. 18, 2013	Dec. 31, 2011
	Security	Security
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Contingent consideration liability	$15,700	$0	$15,900	$0
Auction rate securities	2,208	3,240	'	'
Duration of securities subject to temporary impairment, minimum (in months)	'12 months	'	'	'
Amount of temporary impairment	192	260	'	'
Summarize the amortized cost basis, the aggregate fair value and gross unrealized holding [Abstract]	'	'	'	'
Amortized Cost Basis	2,400	3,500	'	'
Fair Value	2,208	3,240	'	'
Gross Unrealized Holding, Gains	0	0	'	'
Gross Unrealized Holding, Losses	-192	-260	'	'
Gross Unrealized Holding Gains (Losses), Net	-192	-260	'	'
Continuous unrealized loss position, Unrealized Losses [Abstract]	'	'	'	'
Number of securities with gross unrealized loss position	1	2	'	'
Weighted average duration of unrealized losses	'70 months	'58 months	'	'
Contingent consideration liability	15,700	0	15,900	0
Maximum [Member]	'	'	'	'
Continuous unrealized loss position, Unrealized Losses [Abstract]	'	'	'	'
Severity of the unrealized losses below amortized cost (in hundredths)	8.00%	8.00%	'	'
Maturities Greater Than Ten Years [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Amount of temporary impairment	192	200	'	'
Summarize the amortized cost basis, the aggregate fair value and gross unrealized holding [Abstract]	'	'	'	'
Amortized Cost Basis	2,400	2,500	'	'
Fair Value	2,208	2,300	'	'
Gross Unrealized Holding, Gains	0	0	'	'
Gross Unrealized Holding, Losses	-192	-200	'	'
Gross Unrealized Holding Gains (Losses), Net	-192	-200	'	'
Investments Without Stated Maturity Dates [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Amount of temporary impairment	'	60	'	'
Summarize the amortized cost basis, the aggregate fair value and gross unrealized holding [Abstract]	'	'	'	'
Amortized Cost Basis	'	1,000	'	'
Fair Value	'	940	'	'
Gross Unrealized Holding, Gains	'	0	'	'
Gross Unrealized Holding, Losses	'	-60	'	'
Gross Unrealized Holding Gains (Losses), Net	'	-60	'	'
U.S. Government Subsidized Securities [Member] | Minimum [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Maturity period of US government subsidized securities (in years)	'10 years	'	'	'
U.S. Government Subsidized Securities [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Auction rate securities	2,208	'	'	'
Auction Rate Securities [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Auction rate securities	2,208	3,240	'	'
Continuous unrealized loss position, Fair Value [Abstract]	'	'	'	'
Less than 12 Months, Fair Value	0	0	'	'
12 Months or Greater, Fair Value	2,208	3,240	'	'
Total, Fair Value	2,208	3,240	'	'
Continuous unrealized loss position, Unrealized Losses [Abstract]	'	'	'	'
Less than 12 Months, Unrealized Losses	0	0	'	'
12 Months or Greater, Unrealized Losses	-192	-260	'	'
Total, Unrealized Losses	-192	-260	'	'
Recurring [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Contingent consideration liability	15,700	'	'	'
Money market funds	60,364	56,224	'	'
Auction rate securities	2,208	3,240	'	'
Liability, total	15,700	'	'	'
Asset, total	62,572	59,464	'	'
Continuous unrealized loss position, Unrealized Losses [Abstract]	'	'	'	'
Contingent consideration liability	15,700	'	'	'
Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Contingent consideration liability	0	'	'	'
Money market funds	60,364	56,224	'	'
Auction rate securities	0	0	'	'
Liability, total	0	'	'	'
Asset, total	60,364	56,224	'	'
Continuous unrealized loss position, Unrealized Losses [Abstract]	'	'	'	'
Contingent consideration liability	0	'	'	'
Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Contingent consideration liability	0	'	'	'
Money market funds	0	0	'	'
Auction rate securities	0	0	'	'
Liability, total	0	'	'	'
Asset, total	0	0	'	'
Continuous unrealized loss position, Unrealized Losses [Abstract]	'	'	'	'
Contingent consideration liability	0	'	'	'
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'
Contingent consideration liability	15,700	'	'	'
Money market funds	0	0	'	'
Auction rate securities	2,208	3,240	'	'
Liability, total	15,700	'	'	'
Asset, total	2,208	3,240	'	'
Continuous unrealized loss position, Unrealized Losses [Abstract]	'	'	'	'
Contingent consideration liability	$15,700	'	'	'

Fair_Value_Measurements_Part_2

Fair Value Measurements, Part 2 (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Total realized/unrealized gains (losses)	'	'	'
Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date	$68	$8	$24
Azedra commercialization [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Period of milestone expected achievement	'2017	'	'
Fair Value	2,300	'	'
Valuation technique	'Probability adjusted discounted cash flow model	'	'
Discount Rate	10.00%	'	'
Probability of success	40.00%	'	'
Small molecule therapeutics commercialization [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Period of milestone expected achievement	'2021	'	'
Fair Value	500	'	'
Valuation technique	'Probability adjusted discounted cash flow model	'	'
Discount Rate	10.00%	'	'
Probability of success	19.00%	'	'
Net sales targets [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Fair Value	10,900	'	'
Valuation technique	'Monte-Carlo simulation	'	'
Discount Rate	12.50%	'	'
Contingent Consideration Liability [Member]	'	'	'
Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]	'	'	'
Balance at beginning of period	0	0	'
Total realized/unrealized gains (losses)	'	'	'
Fair value of contingent consideration - acquisition of Molecular Insight	15,900	0	'
Fair value adjustment to contingent consideration included in net loss	-200	0	'
Balance at end of period	15,700	0	'
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for assets or liabilities held at the end of the reporting period	-200	0	'
MIP - 1404 commercialization [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Period of milestone expected achievement	'2018	'	'
Fair Value	2,000	'	'
Valuation technique	'Probability adjusted discounted cash flow model	'	'
Discount Rate	10.00%	'	'
Probability of success	31.00%	'	'
Auction Rate Securities [Member]	'	'	'
Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]	'	'	'
Balance at beginning of period	3,240	3,332	'
Transfers into Level 3	0	0	'
Total realized/unrealized gains (losses)	'	'	'
Included in net income (loss)	0	0	'
Included in comprehensive income (loss)	68	8	'
Settlements	-1,100	-100	'
Balance at end of period	2,208	3,240	'
Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date	0	0	'
Fair Value Measurements, Quantitative Information	'	'	'
Fair Value	$2,208	$3,240	'
Valuation technique	'Discounted cash flow model	'Discounted cash flow model	'
Minimum [Member] | Net sales targets [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Period of milestone expected achievement	'2018	'	'
Probability of success	19.00%	'	'
Minimum [Member] | Auction Rate Securities [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Redemption period	'5 years	'4 years	'
Discount Rate	0.25%	0.13%	'
Maximum [Member] | Net sales targets [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Period of milestone expected achievement	'2022	'	'
Probability of success	40.00%	'	'
Maximum [Member] | Auction Rate Securities [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Redemption period	'15 years	'15 years	'
Discount Rate	3.00%	2.10%	'
Weighted average [Member] | Net sales targets [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Probability of success	32.80%	'	'
Weighted average [Member] | Auction Rate Securities [Member]	'	'	'
Fair Value Measurements, Quantitative Information	'	'	'
Redemption period	'6 years	'5 years 10 months 24 days	'
Discount Rate	1.55%	0.71%	'

Accounts_Receivable_Details

Accounts Receivable (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	$2,879	$6,937
Allowance for Doubtful Accounts Receivable	-7	0
Collaborators [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	12	6,125
Royalties [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	2,862	781
Research grants [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	0	12
Other [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	12	19
Subtotal [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Accounts receivable	$2,886	$6,937

Fixed_Assets_Details

Fixed Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fixed Assets [Abstract]	'	'
Leasehold improvements, net	2,000,000	2,600,000
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	14,531,000	15,669,000
Less, accumulated depreciation and amortization	-12,118,000	-12,270,000
Fixed assets, total	2,413,000	3,399,000
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	2,234,000	2,166,000
Estimated useful life	'3 years	'
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	7,091,000	8,031,000
Machinery and Equipment [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated useful life	'5 years	'
Machinery and Equipment [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated useful life	'7 years	'
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	170,000	133,000
Estimated useful life	'5 years	'
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	5,020,000	5,327,000
Leasehold Improvements [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated useful life	'8 years 6 months	'8 years 6 months
Leasehold Improvements [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Estimated useful life	'10 years 9 months 18 days	'10 years 9 months 18 days
Construction in Progress and Other [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Fixed assets, gross	16,000	12,000

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts payable and accrued expenses [Abstract]	'	'
Accrued consulting and clinical trial costs	$2,672	$2,193
Accrued payroll and related costs	2,123	1,552
Restructuring accrual	0	813
Legal and professional fees	608	774
Accounts payable	793	229
Other	316	79
Total	$6,512	$5,640

Restructuring_Details

Restructuring (Details) (USD $)	3 Months Ended			6 Months Ended	12 Months Ended
	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring [Abstract]	'	'	'	'	'	'	'
Restructuring accrual of severance and related benefits	'	$1,500,000	$1,900,000	$1,300,000	'	'	'
Lease termination payments	1,359,000	'	'	'	'	'	'
Activity in restructuring accrual [Roll Forward]	'	'	'	'	'	'	'
Balance at beginning of period	'	813,000	'	'	813,000	731,000	0
Additions, net	'	'	'	'	2,866,000	2,092,000	1,641,000
Payments	'	'	'	'	-3,679,000	-2,010,000	-910,000
Balance at end of period	'	'	'	731,000	0	813,000	731,000
Severance and Related Benefits [Member]	'	'	'	'	'	'	'
Activity in restructuring accrual [Roll Forward]	'	'	'	'	'	'	'
Balance at beginning of period	'	813,000	'	'	813,000	571,000	0
Additions, net	'	'	'	'	1,492,000	1,905,000	1,341,000
Payments	'	'	'	'	-2,305,000	-1,663,000	-770,000
Balance at end of period	'	'	'	571,000	0	813,000	571,000
Other Exit Costs [Member]	'	'	'	'	'	'	'
Activity in restructuring accrual [Roll Forward]	'	'	'	'	'	'	'
Balance at beginning of period	'	0	'	'	0	6,000	0
Additions, net	'	'	'	'	15,000	184,000	8,000
Payments	'	'	'	'	-15,000	-190,000	-2,000
Balance at end of period	'	'	'	6,000	0	0	6,000
Contract Termination Costs [Member]	'	'	'	'	'	'	'
Activity in restructuring accrual [Roll Forward]	'	'	'	'	'	'	'
Balance at beginning of period	'	0	'	'	0	154,000	0
Additions, net	'	'	'	'	1,359,000	3,000	292,000
Payments	'	'	'	'	-1,359,000	-157,000	-138,000
Balance at end of period	'	'	'	$154,000	$0	$0	$154,000

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jul. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stockholders' Equity [Abstract]	'	'	'	'	'
Common stock, authorized (in shares)	'	'	160,000,000	80,000,000	'
Common stock, par value (in dollars per share)	'	'	$0.00	$0.00	'
Preferred stock, authorized (in shares)	'	'	20,000,000	20,000,000	'
Preferred stock, par value (in dollars per share)	'	'	$0.00	$0.00	'
Common Stock sold in public offering (in shares)	9,775,000	8,750,000	9,800,000	'	'
Proceeds from public offering of common stock, net of underwriting discounts and commissions and offering expenses	$40,100	$37,500	$40,078	$23,348	$0

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Future minimum annual payments under operating lease agreements [Abstract]	'	'	'
2014	$1,841	'	'
2015	1,887	'	'
2016	1,934	'	'
2017	1,983	'	'
2018	2,032	'	'
Thereafter	4,218	'	'
Total	13,895	'	'
Rental expense	3,548	2,074	3,475
Adjustments to rental expense	-164	-419	63
Additional facility charges	2,330	2,845	4,033
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
License fees and supply costs	567	1,170	578
Consulting Agreements [Abstract]	'	'	'
Expenses with regard to consulting agreements with scientific specialists	39	8	27
Fair value of options vested included in consulting expenses	7	'	11
Retirement Agreement [Abstract]	'	'	'
Expenses for termination of employment agreement	'	1,789	'
MTS-Related Party Agreement	'	'	'
Consulting agreement monthly retainer amount	55	'	'
Success fee	300	'	'
Parent Company [Member] | Lonza Sales AG [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Commitments, paid from inception	909	'	'
Future Commitments	824	'	'
Terms	'Annual license fee payments, milestones and royalties, as applicable, in respect of oncology and other products.	'	'
PSMA Development Company LLC [Member] | Seattle Genetics, Inc. [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Commitments, paid from inception	4,400	'	'
Future Commitments	13,900	'	'
PSMA Development Company LLC [Member] | Amgen Fremont, Inc. (formerly Abgenix) [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Commitments, paid from inception	1,350	'	'
Future Commitments	5,750	'	'
PSMA Development Company LLC [Member] | Former Member of PSMA LLC [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Commitments, paid from inception	278	'	'
Future Commitments	52,188	'	'
Terms	'Annual minimum royalty payments and milestones to use technology related to PSMA.	'	'
MIP [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Commitments, paid from inception	216	'	'
Future Commitments	3,453	'	'
MIP [Member] | Seattle Genetics, Inc. [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Terms	'Milestone and periodic maintenance payments to use ADC technology to link chemotherapeutic agents to monoclonal antibodies that target prostate specific membrane antigen. ADC technology is based in part on technology licensed by SGI from third parties.	'	'
MIP [Member] | Amgen Fremont, Inc. (formerly Abgenix) [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Terms	'Milestones and royalties to use XenoMouseB. technology for generating fully human antibodies to PSMA LLCbs PSMA antigen.	'	'
MIP [Member] | Former Member of PSMA LLC [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Terms	'Payments for programs to be out-licensed or terminated	'	'
MIP [Member] | University of Zurich and the Paul Scherrer Institute [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Commitments, paid from inception	65	'	'
Future Commitments	1,225	'	'
Terms	'Annual maintenance and license fee payments, milestones and royalties in respect of licensed technology related to 1404.	'	'
MIP [Member] | University of Western Ontario [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Commitments, paid from inception	4	'	'
Future Commitments	374	'	'
Terms	'Annual minimum royalty, administration and milestone payments in respect of licensed technology related to Azedra.	'	'
MIP [Member] | Novartis Pharma AG and other interests [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Commitments, paid from inception	0	'	'
Future Commitments	4,600	'	'
Terms	'Milestone and royalty payments in respect of licensed technology related to Onalta.	'	'
MIP [Member] | Bayer Schering Pharma AG [Member]	'	'	'
Licensing, Service, Supply and Related Party Agreements [Abstract]	'	'	'
Commitments, paid from inception	0	'	'
Future Commitments	$9,000	'	'
Terms	'Milestone and royalty payments in respect of licensed technology related to a MIP asset.	'	'

ShareBased_Payment_Arrangement2

Share-Based Payment Arrangements (Details) (USD $)	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of stock incentive plans	2	'	'
Number of employee stock purchase plans	2	'	'
Options, Outstanding [Roll Forward]	'	'	'
Outstanding, Beginning balance (in shares)	5,366	'	'
Granted (in shares)	1,018	'	'
Exercised (in shares)	-14	'	'
Forfeited	-608	'	'
Expired	-463	'	'
Outstanding, Ending balance (in shares)	5,299	5,366	'
Exercisable (in shares)	3,875	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Outstanding, Beginning balance (in dollars per share)	$12.27	'	'
Granted (in dollars per share)	$5.13	'	'
Exercised (in dollars per share)	$5.08	'	'
Forfeited (in dollars per share)	$10.63	'	'
Expired (in dollars per share)	$14.70	'	'
Outstanding, Ending balance (in dollars per share)	$10.89	$12.27	'
Exercisable (in dollars per share)	$12.45	'	'
Weighted Average Remaining Contractual Term [Abstract]	'	'	'
Options Outstanding	'5 years 9 months 25 days	'	'
Options Exercisable	'4 years 10 months 10 days	'	'
Aggregate Intrinsic Value [Abstract]	'	'	'
Options Outstanding	$304,000	'	'
Options Exercisable	118,000	'	'
Total compensation expense recognized	3,546,000	6,536,000	6,362,000
Employee stock purchase plan [Abstract]	'	'	'
Cash received from exercises under all share-based payment arrangements	100,000	'	'
Employees [Member]	'	'	'
Assumptions used in computing the fair value [Abstract]	'	'	'
Expected term	'5 years 4 months 24 days	'5 years 3 months 18 days	'5 years 3 months 18 days
Former CEO [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Vesting period	'9 years 11 months	'	'
Assumptions used in computing the fair value [Abstract]	'	'	'
Expected term	'	'	'8 years
Aggregate Intrinsic Value [Abstract]	'	'	'
Estimated requisite service periods	'9 years 11 months	'	'
Non Employees [Member]	'	'	'
Assumptions used in computing the fair value [Abstract]	'	'	'
Expected term	'10 years	'	'
Directors and Officers [Member]	'	'	'
Assumptions used in computing the fair value [Abstract]	'	'	'
Expected term	'7 years 4 months 24 days	'7 years 4 months 24 days	'7 years 3 months 18 days
Options [Member]	'	'	'
Assumptions used in computing the fair value [Abstract]	'	'	'
Expected volatility, minimum (in hundredths)	73.00%	70.00%	68.00%
Expected volatility, maximum (in hundredths	90.00%	85.00%	78.00%
Expected dividends (in hundredths)	0.00%	0.00%	0.00%
Weighted average expected term (years)	'5 years 11 months 16 days	'6 years 1 month 10 days	'6 years 2 months 1 day
Risk-free rate, minimum (in hundredths)	0.76%	0.57%	0.77%
Risk-free rate, maximum (in hundredths)	2.83%	1.71%	2.97%
Employee stock purchase plan [Abstract]	'	'	'
Total unrecognized compensation	4,400,000	'	'
Weighted average periods	'2 years 1 month 6 days	'	'
Options [Member] | Minimum [Member]	'	'	'
Assumptions used in computing the fair value [Abstract]	'	'	'
Expected term	'5 years 3 months 18 days	'5 years 3 months 18 days	'5 years 3 months 18 days
Options [Member] | Maximum [Member]	'	'	'
Assumptions used in computing the fair value [Abstract]	'	'	'
Expected term	'10 years	'10 years	'10 years
Restricted stock [Member]	'	'	'
Restricted Stock [Roll Forward]	'	'	'
Nonvested, Beginning balance (in shares)	28	'	'
Granted (in shares)	0	'	'
Vested (in shares)	-27	'	'
Forfeited (in shares)	-1	'	'
Nonvested, Ending balance (in shares)	0	'	98
Restricted Stock, Weighted Average Grant-Date Fair Value [Roll Forward]	'	'	'
Nonvested, Beginning balance (in dollars per share)	$5.35	'	'
Granted (in dollars per share)	$0	'	'
Vested (in dollars per share)	$5.35	'	'
Forfeited (in dollars per share)	$5.35	'	'
Nonvested, Ending balance (in dollars per share)	$0	'	'
Performance-based options [Member]	'	'	'
Aggregate Intrinsic Value [Abstract]	'	'	'
Total compensation expense recognized	100,000	2,000,000	400,000
2006 Award [Member] | Options [Member]	'	'	'
Aggregate Intrinsic Value [Abstract]	'	'	'
Estimated requisite service periods	'2 years 6 months	'	'
2011 Award [Member] | Options [Member]	'	'	'
Aggregate Intrinsic Value [Abstract]	'	'	'
Estimated requisite service periods	'1 year	'	'
2012 Award [Member] | Options [Member]	'	'	'
Aggregate Intrinsic Value [Abstract]	'	'	'
Estimated requisite service periods	'1 year	'	'
1996 Plan and 2005 Plan [Member] | Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expiration term	'10 years	'	'
Aggregate Intrinsic Value [Abstract]	'	'	'
Weighted average grant-date fair value of options granted (in dollars per share)	$3.74	$6.38	$5.51
Total Intrinsic Value of options exercised	$11,000	$174,000	$345,000
1996 Plan and 2005 Plan [Member] | Options [Member] | Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Vesting period	'3 years	'	'
1996 Plan and 2005 Plan [Member] | Options [Member] | Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Vesting period	'5 years	'	'
1996 Plan and 2005 Plan [Member] | Restricted stock [Member] | Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Vesting period	'3 years	'	'
1996 Plan and 2005 Plan [Member] | Restricted stock [Member] | Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Vesting period	'5 years	'	'
1996 Amended Stock Incentive Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Common stock reserved for issuance of awards (in shares)	5,000	'	'
2005 Stock Incentive Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Common stock reserved for issuance of awards (in shares)	8,450	'	'
Employee Stock Purchase Plan [Member]	'	'	'
Assumptions used in computing the fair value [Abstract]	'	'	'
Expected volatility, minimum (in hundredths)	'	'	43.00%
Expected volatility, maximum (in hundredths	'	'	51.00%
Expected dividends (in hundredths)	'	'	0.00%
Expected term	'	'	'6 months
Risk-free rate, minimum (in hundredths)	'	'	0.06%
Risk-free rate, maximum (in hundredths)	'	'	0.22%
Employee Stock Purchase Plan [Member] | Options [Member]	'	'	'
Assumptions used in computing the fair value [Abstract]	'	'	'
Expected term	'	'	'6 months
Restricted Stock, Weighted Average Grant-Date Fair Value [Roll Forward]	'	'	'
Percentage of quarterly compensation, grant to all employees (in hundredths)	'	'	25.00%
Discounted price as percentage of the fair market value (in hundredths)	'	'	85.00%
Qualified Employee Stock Purchase Plan 1998 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Common stock reserved for issuance of awards (in shares)	4,400	'	'
Employee stock purchase plan [Abstract]	'	'	'
Shares Purchased (in shares)	'	'	428
Weighted Average Grant-date Fair value (in dollars per share)	'	'	$0.88
Qualified Employee Stock Purchase Plan 1998 [Member] | Minimum [Member]	'	'	'
Employee stock purchase plan [Abstract]	'	'	'
Price Range (in dollars per share)	'	'	$4.62
Qualified Employee Stock Purchase Plan 1998 [Member] | Maximum [Member]	'	'	'
Employee stock purchase plan [Abstract]	'	'	'
Price Range (in dollars per share)	'	'	$5.65
Qualified Employee Stock Purchase Plan 1998 [Member] | Options [Member]	'	'	'
Restricted Stock, Weighted Average Grant-Date Fair Value [Roll Forward]	'	'	'
Maximum percentage of common stock ownership to be eligible for employee stock purchase plans (in hundredths)	'	'	5.00%
Non-Qualified Employee Purchase Plan 1998 [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Common stock reserved for issuance of awards (in shares)	1,100	'	'
Employee stock purchase plan [Abstract]	'	'	'
Shares Purchased (in shares)	'	'	162
Weighted Average Grant-date Fair value (in dollars per share)	'	'	$0.84
Non-Qualified Employee Purchase Plan 1998 [Member] | Minimum [Member]	'	'	'
Employee stock purchase plan [Abstract]	'	'	'
Price Range (in dollars per share)	'	'	$4.62
Non-Qualified Employee Purchase Plan 1998 [Member] | Maximum [Member]	'	'	'
Employee stock purchase plan [Abstract]	'	'	'
Price Range (in dollars per share)	'	'	$5.65

ShareBased_Payment_Arrangement3

Share-Based Payment Arrangements, Allocation of Recognized Period Costs (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total compensation expense recognized	$3,546	$6,536	$6,362
Research and Development [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total compensation expense recognized	2,524	4,568	4,499
General and Administrative [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Total compensation expense recognized	$1,022	$1,968	$1,863

Employee_Savings_Plan_Details

Employee Savings Plan (Details) (USD $)	12 Months Ended			36 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Employee Savings Plan [Abstract]	'	'	'	'
Matching contribution (in hundredths)	'	'	'	50.00%
Minimum contribution as percentage of compensation (in hundredths)	'	'	'	5.00%
Maximum contribution as percentage of compensation (in hundredths)	'	'	'	8.00%
Contributions by employer	$330	$535	$597	'
Employer discretionary contribution	$0	$0	$0	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jan. 18, 2013
Income Taxes [Abstract]	'	'	'	'
Income tax provision (benefit)	($362,000)	$0	$0	'
Deferred tax assets and liabilities [Abstract]	'	'	'	'
Depreciation and amortization	6,165,000	6,497,000	'	'
R&E tax credit carry-forwards	5,129,000	11,843,000	'	'
NYS investment tax credit carry-forwards	1,095,000	1,084,000	'	'
AMT credit carry-forwards	211,000	211,000	'	'
Net operating loss carry-forwards	190,263,000	112,966,000	'	'
Capitalized research and development expenditures	25,231,000	30,884,000	'	'
Stock compensation	13,826,000	14,436,000	'	'
Other items	1,097,000	2,193,000	'	'
Total gross deferred tax assets	243,017,000	180,114,000	'	'
Less: Valuation allowance	-243,017,000	-178,045,000	'	'
Deferred tax assets	0	2,069,000	'	'
Deferred tax liability - current	0	-2,069,000	'	'
Deferred tax liability - long term	-12,321,000	0	'	-12,683,000
Net deferred tax asset (liability)	-12,321,000	0	'	'
Deferred tax assets, net, current	'	17,000	'	'
Deferred tax assets, net, noncurrent	0	2,052,000	'	'
Reconciliation of income taxes computed at the Federal statutory income tax rate to the actual effective income tax [Abstract]	'	'	'	'
U.S. Federal statutory rate (in hundredths)	-34.00%	-35.00%	35.00%	'
State income taxes, net of Federal benefit (in hundredths)	-4.90%	-5.40%	8.00%	'
Research and experimental tax credit (in hundredths)	-3.60%	0.00%	-4.10%	'
Change in valuation allowance (in hundredths)	11.40%	34.70%	-22.60%	'
Effect of federal tax rate bracket change on valuation allowance (in hundredths)	8.70%	0.00%	-34.80%	'
Equity compensation (in hundredths)	3.10%	4.20%	17.00%	'
Investment tax credit (in hundredths)	-0.10%	0.00%	-0.10%	'
NOL expiration - Section 382	18.60%	0.00%	0.00%	'
Other (in hundredths)	0.00%	1.50%	1.60%	'
Income tax provision (benefit) (in hundredths)	-0.80%	0.00%	0.00%	'
Net operating loss carryforwards - federal	513,800,000	'	'	'
Net operating loss carryforwards - state	453,100,000	'	'	'
Unrecognized tax benefit amount that would affect effective tax rate	0	'	'	'
Net operating loss carry-forwards not reflected in deferred tax assets	18,200,000	'	'	'
Valuation allowance related to net operating loss carryforwards attributable to excess tax deductions for equity compensation	11,200,000	'	'	'
Unrecognized tax benefits	-362,000	0	0	'
Tax credit carryforwards of R&E expired	20,000	'	'	'
Deferred tax assets	0	2,069,000	'	'
Deferred Tax Liabilities, Net, Current	0	2,069,000	'	'
Deferred tax liability - long term	12,321,000	0	'	12,683,000
Tax Credit Carryforward, Amount	5,100,000	'	'	'
Income Taxes [Abstract]	'	'	'	'
Unrecognized tax benefits	2,661,000	2,661,000	'	'
Current year - increases	0	'	'	'
Current year - decreases	0	'	'	'
Settlements	0	'	'	'
Expired statuses	$0	'	'	'

Net_Income_Loss_Per_Share_Deta

Net Income (Loss) Per Share (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net Income (Loss) (Numerator) [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net income (loss), basic	'	'	'	'	'	'	'	'	'	'	$10,381
Dilutive effect of stock options	'	'	'	'	'	'	'	'	'	'	0
Dilutive effect of restricted stock	'	'	'	'	'	'	'	'	'	'	0
Net income (loss), diluted	'	'	'	'	'	'	'	'	'	'	10,381
Net income (loss), basic and diluted	($8,551)	($10,500)	($12,263)	($11,258)	($324)	($11,301)	($10,720)	($13,086)	($42,572)	($35,431)	$10,381
Weighted Average Common Shares (Denominator) Abstract	'	'	'	'	'	'	'	'	'	'	'
Shares outstanding, Basic (in shares)	'	'	'	'	'	'	'	'	55,798	34,754	33,375
Dilutive effect of stock options (in shares)	'	'	'	'	'	'	'	'	'	'	66
Dilutive effect of restricted stock (in shares)	'	'	'	'	'	'	'	'	'	'	53
Shares outstanding, Diluted (in shares)	'	'	'	'	'	'	'	'	55,798	34,754	33,494
Shares outstanding, Basic and Diluted (in shares)	'	'	'	'	'	'	'	'	55,798	34,754	'
Per share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net income (loss) per share, basic (in dollars per share)	'	'	'	'	'	'	'	'	($0.76)	($1.02)	$0.31
Net income (loss) per share, diluted (in dollars per share)	'	'	'	'	'	'	'	'	($0.76)	($1.02)	$0.31
Net income (loss) per share, basic and diluted (in dollars per share)	($0.14)	($0.17)	($0.24)	($0.22)	($0.01)	($0.33)	($0.32)	($0.39)	($0.76)	($1.02)	'
Anti-dilutive common shares excluded from diluted per share amounts [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Weighted Average Number (in shares)	'	'	'	'	'	'	'	'	5,969	6,007	4,588
Options [Member]	'	'	'	'	'	'	'	'	'	'	'
Anti-dilutive common shares excluded from diluted per share amounts [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Weighted Average Number (in shares)	'	'	'	'	'	'	'	'	5,969	5,947	4,543
Weighted Average Exercise Price (in dollars per share)	'	'	'	'	'	'	'	'	$11.54	$12.32	$14.92
Restricted stock [Member]	'	'	'	'	'	'	'	'	'	'	'
Anti-dilutive common shares excluded from diluted per share amounts [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Shares of unvested restricted stock outstanding (in shares)	0	'	'	'	28	'	'	'	0	28	98
Weighted Average Number (in shares)	'	'	'	'	'	'	'	'	0	60	45

Unaudited_Quarterly_Results_un2

Unaudited Quarterly Results (unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$2,968	$867	$1,801	$2,226	$8,885	$1,117	$1,820	$2,226	$7,862	$14,048	$84,796
Net income (loss)	-8,551	-10,500	-12,263	-11,258	-324	-11,301	-10,720	-13,086	-42,572	-35,431	10,381
Net income (loss) per share - basic and diluted (in dollars per share)	($0.14)	($0.17)	($0.24)	($0.22)	($0.01)	($0.33)	($0.32)	($0.39)	($0.76)	($1.02)	'
MedImmune [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	5,000	'	'	'	'	'	'	'	'	'	'
CytoDyn [Member]	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$2,800	'	'	'	'	'	'	'	'	'	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jul. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Subsequent Events [Abstract]	'	'	'	'	'
Common Stock sold in public offering (in shares)	9,775	8,750	9,800	'	'
Common stock offering price	'	$4.60	$4.40	'	'
Proceeds from public offering of common stock, net of underwriting discounts and commissions and offering expenses	$40,100,000	$37,500,000	$40,078,000	$23,348,000	$0
Shelf registration established	'	150,000,000	'	'	'
Superseded registration	'	$31,700,000	'	'	'

Schedule_II_Valuation_and_Qual1

Schedule II - Valuation and Qualifying Accounts (Details) (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts [Member]	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'
Beginning balance	$7	$0
Additions	7	'
Deductions	0	'
Ending balance	$7	$0